No Challenge Too Big.
No Patient Too Small.

Discover the Masimo SET® Difference

For over 25 years, Masimo has been a trusted partner in neonatal and newborn care around the world—delivering innovative Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry to enhance care even in challenging conditions.

Today, we remain committed to protecting your most delicate patients and strive to deliver a variety of specially tailored solutions that meet their needs and help you improve outcomes.

To learn more about how SET® is making a difference for neonates, visit masimo.com/newborn-care

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, and precautions.

© 2021 Masimo. All rights reserved.
9 Days Old

It’s never too early to...

- Reduce Secretions
- Improve Swallowing
- Reduce Risk of Infection
- Improve Olfaction
- Reduce Decannulation Time
- Facilitate Weaning
- Vocalize (cry and coo)

To find out more, visit www.passymuir.com

Look for the Purple Valve
the only Valve backed by mountains of research

Passy Muir
Millions of Voices, ONE VALVE™

Love at first sound

Check out our new FREE LIVE event webinars
www.passymuir.com/remote-live-inservices
DEPARTMENTS
6 Letter to the Editor
7 News

ARTICLES
16 Using Near-Infrared Spectroscopy to Guide Your Clinical Decision Making
19 The Risk of Mortality for Patients with Persistently Elevated HeRO Scores
22 A New System of Vitamin Administration During Pregnancy and Postpartum
24 Noninvasive Technique to Track Early Preemies’ Cerebral Oxygen Levels
25 Considerations for the Impact of a Tracheostomy
29 A Nutritional Approach to Feeding a Targeted Bacterial Strain
32 What Clinicians Need to Know About Human Milk Banking
39 The ENFit Enteral-Only System
42 The Benefits of Personalized Lung Protection and Weaning Positioning
46 A New Standard in Developmental Positioning
49 Incidence of Urinary Tract Infection in Neonates with Significant Indirect Hyperbilirubinemia of Unknown Etiology
55 Circulating Tight-Junction Proteins Are Potential Biomarkers for Blood-Brain Barrier Function

Editorial Advisory Board

Arie L. Alkalay, MD
Clinical Professor of Pediatrics
David Geffen School of Medicine
Pediatrician, Cedars-Sinai
Los Angeles, CA

M. A. Arif, MD
Professor of Pediatrics & Head, Neonatology
National Institutes of Child Health
Karachi, Pakistan

Muhammad Aslam, MD
Associate Professor of Pediatrics
University of California, Irvine
Neonatologist, UC Irvine Medical Center
Orange, CA

Edward Austin, MD
Austen-Henderson Family Medical Center
Compton, CA

Richard L. Auten, MD
Assistant Professor of Pediatrics
Duke University Medical Center
Durham, NC

Bruce G. Bateman, MD
Department of Obstetrics & Gynecology
University of Virginia
Charlottesville, VA

Sandy Beausum, MSN, RN-C, NIC
CNE, Consulting
Albuquerque, NM

David D. Berry, MD
Wake Forest University School of Medicine
Winston-Salem, NC

Melissa K. Brown, BS, RRT-NPS, RCP
Faculty, Respiratory Therapy Program
Grossmont College
El Cajon, CA

D. Spencer Brudno, MD
Associate Professor of Pediatrics
Medical Director, Pediatric Therapy
Medical College of Georgia
Augusta, GA

Curtis D. Caldwell, NNP
UNM School of Medicine, Dept of Pediatrics
Albuquerque, NM

Ed Coombs, MA, RRT-NPS, ACCS, FAARC
Marketing Director – Intensive Care
Key Application Field Manager – Respiratory Care, Draeger Medical
Telford, PA

Jonathan Cronin, MD
Assistant Professor of Pediatrics
Hanford Medical School Chief
Neonatology and Newborn Medicine Unit
Department of Pediatrics
Massachusetts General Hospital for Children
Boston, MA

Michael P. Czervinski, RRT
Neonatal and Pediatric Critical Care
University of Kansas Medical Center
Kansas City, KS

Professor Adekunle H. Dawodu
Director, International Patient Care and Education, Cincinnati Children’s Hospital
Cincinnati, OH

Jayant Deodhar, MD
Associate Professor of Clinical Pediatrics
Children’s Hospital Center
Hartford, CT

Leonard Eisenfeld, MD
Associate Professor of Pediatrics
University of Connecticut School of Medicine
Division of Neonatology
Connecticut Children’s Medical Center
Hartford, CT

Sam Eshhassani, MD
Neonatologist
Spartanburg, SC

Ivan Frantz, III, MD
Chairman of Department of Pediatrics
Chief, Division of Neonatology
Tufts University School of Medicine
Boston, MA

Philippe S. Friedlich, MD
Associate Professor of Clinical Pediatrics
Children’s Hospital of Los Angeles
Los Angeles, CA

G. Paolo Gancia, MD
Neonatologist, Terapia Intensiva
Neonatale-Neonatologia, Coneo, Italy

George A. Gregory, MD
Professor of Pediatrics and Anesthesia
University of California
San Francisco, CA

Charles J. Gutierrez, PhD, RRT, FAARC
Neurorespiratory Clinical Specialist, J.A.
Hailey VA Hospital and Assistant Professor, Pulmonary, Critical Care & Sleep Medicine, Mirmar College of Medicine, University of South Florida, Tampa, FL

William R. Halliburton, RRT, RCP
Neonatal Respiratory Care Coordinator
Department of Respiratory Care
Hillcrest Baptist Medical Center, Waco, TX

Mary Catherine Harris, MD
Associate Professor of Pediatrics
University of Pennsylvania School of Medicine
The Children’s Hospital of Philadelphia
Philadelphia, PA

David J. Hoffman, MD
Clinical Associate Professor of Pediatrics
Penn State College of Medicine
Staff Neonatologist
The Reading Hospital and Medical Center
West Reading, PA

Michael R. Jackson, RRT
Newborn Intensive Care Unit
Beth Israel Hospital, Boston, MA

Chang-Ryu Kim, MD
Associate Professor of Pediatrics
Korea University College of Medicine
Seoul, South Korea

David M. Kissin, BS, RRT
Perinatal/Pediatric Specialist
Maine Medical Center, Portland, ME

Sheldon Koravangattu, MD
Director of Newborn Center
College of Medicine, Memphis, TN

Scott E. Leonard, MD, RRT
Director of Respiratory Therapy, EGG, Neuropulmonary
George Washington University Hospital
Washington, DC

Raymond Malloy, MHA, RRT
Director of Pulmonary Care
Thomas Jefferson University Hospital
Philadelphia, PA

Paul J. Mathews, PhD, RRT, FCCM, FCCP, FAARC
Associate Professor of Respiratory Care
University of Kansas Medical Center
Kansas City, KS

William Meadow, MD
Professor of Pediatrics
Co-Section Chief, Neonatology
Comer Children’s Hospital
The University of Chicago, Chicago, IL

David G. Oelberg, MD
Center for Pediatric Research
Eastern Virginia Medical School
Children’s Hospital of The King’s Daughters
Norfolk, VA

Ramzi Ora, MD
Director, Department of Neonatology and Pediatrics
Professor of Pediatrics and Neonatologist
Maimonides Medical Faculty
Neommitmotn Erubian University
Konya, Turkey

T. Michael O’Shea, MD, MPH
Chief, Neonatology Division
Wake Forest University School of Medicine
Winston-Salem, NC

Lisa Pappas, RRT-NPS
Respiratory Clinical Coordinator NICU
University of Utah Hospital
Salt Lake City, UT

G. Battista Purigi, MD
Associate Professor of Pediatric Surgery
University of Pavia, Italy

Richard Pau, MD
Chief, Materita & Fetal Medicine
Department of Obstetrics & Gynecology
University of Southern California
Los Angeles, CA

Max Perlman, MD
Professor of Pediatrics
The Hospital for Sick Children
Toronto, Ontario, Canada

Boris Petrikovsky
Director, Perinatal Diagnostic Unit Services
New York Downtown Hospital
New York, NY

Arun Pramanik, MD
Professor of Pediatrics
Director of Neonatal Fellowship
Louisiana State University
Health Sciences Center, Shreveport, LA

Benjaminahalli K. Rajegowda, MD
Chief of Neonatology
Lincoln Medical and Mental Health Center
Professor of Clinical Pediatrics
Weill Medical College of Cornell University, NY

Ruben D Restrepo, MD, RRT FAARC FCPM
Coordinator of Research
Professor – Division of Respiratory Care
UT Health San Antonio
7703 Floyd Curl Dr, San Antonio, TX

Koravangattu Sankaran, FRPCIC, FAARC, FCM
Professor of Pediatrics and Director of Neonatology and Neonatal Research
Department of Pediatrics
Royal University Hospital
University of Saskatchewan
Saskatoon, Saskatchewan, Canada

István Seri, MD, PhD
Professor of Pediatrics
Head, USC Division of Neonatal Medicine
University of Southern California
Los Angeles, CA

Tushar A. Shah, MD, MPH
Division of Neonatology
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH

Dave Swift, RRT
Ottawa Hospital – Civic Site
Campus Coordinator (professional Practice) & Special Care Nursery Charge Therapist
Respiratory Therapy Team Lead
National Office of the Health Care Emergency Response Team (NOHERT)
Subject Matter Expert, Health Canada

Jack Tanner
NICO Clinical Coordinator
U Mass Memorial Hospital
Worcester, MA

Otwell D. Timmons, MD
Department of Pediatrics
University of Alabama
Charlottesville, VA

Maya Vazirani, MD, FAAP
Board Certified Neonatology and Pediatrics
Lancaster, CA

Max Vento, MD
Associate Professor of Pediatrics
Chief, Pediatric Services
Neonatology Hospital/Virgin del Consuelo
Valencia, Spain

Dharmapuri Vidyasagar, MD
Professor of Pediatrics
Department of Pediatrics
University of Illinois
Chicago, IL

V+, medline, PubMed, Google Scholar. PUBMED: FEEDING AND WEANING, BLOOD BARRIER
A Hug Makes You Smile!

Introducing NeoHug® Smile Utility Device Holder

Add a splash of color and character to the incubators in your unit. NeoHug is a cute and versatile NICU accessory, ideal for holding a pacifier, suction tip, tape and more.

Available with NEW smile logo design or original chimp in five bright colors. With suction cup for use in incubator or C-clip for use on IV pole.
Dear Dr Campbell:

I am writing to you regarding your analysis of the study that was originally published by Khoury R et al. in the November 2020 issue of the *Journal of Perinatology*. In this study, Khoury R et al. analyzed the performance of two pulse oximeters in a normal cohort of newborn infants during their transition period. Pulse oximetry heart rate stability was recorded “qualitatively” by manually identifying when the oximeter achieved stability as identified by the observer.

There were multiple concerns with the study, including the fact that this study was conducted only in healthy newborns, those least likely to require extensive resuscitation. As a consequence of the restatement of the AAP guidance regarding resuscitation in the delivery room in 2015, Masimo developed a sensor that was specifically designed to operate in this environment. The sensor provided better performance, especially in pulse rate stability, than that which was used in the study. Further, this sensor was optimized to automatically transition the monitor to a 2-second averaging time and maximal sensitivity. Neither of these refinements was incorporated into the study. Studying this pulse oximeter without the benefit of these modes completely invalidates the findings. When comparing oximetry technologies, it is critically important that the latest technologies from each manufacturer be used.

Moreover, the study attempted to clarify pulse rate using heart rate as a gold standard for comparison. It is well known that not all ECG electrical activity translates to a heartbeat, and thus a pulse. Pulseless electrical activity (PEA) is a well-recognized phenomenon in the neonatal population. ECG signals can provide a reliable indication of electrical heart activity but cannot predict with absolute certainty the presence of a heartbeat in association with each waveform. Further, an algorithm predicated on the generation of a stable heart rate as opposed to one that genuinely identifies “missed” beats may be closer to the ECG rate but not accurately reflect the presence of a pulse. The bradycardia reported by Masimo may have accurately reflected actual pulsatile activity.

The authors of the study generalized their concern about their findings and the presence of false bradycardia in resuscitation. The need for resuscitation is typically associated with decreased perfusion, unstable heart rate, and abrupt changes in oximetry. PR stability is an inferior metric during these situations. These are areas where Masimo SET technology has been shown to have superior performance in myriad studies. For a pulse oximeter to...
prove its mettle, it is inappropriate to suggest that “fair weather” conditions in normal transitioning neonates are in any way similar to those encountered during a full-on resuscitation.  

These concerns were also addressed in a letter to the editor that appeared in the March 2021 Neonatology Today authored by Dr Latorre and corroborated by the response, “Speed of response, notwithstanding, the technology is not just about speed alone. Accuracy, precision, and reproducibility are a sine qua non.”

Sincerely,

Mitchell Goldstein, MD, MBA, CML
Professor of Pediatrics
Division of Neonatology
Loma Linda University Children’s Hospital
Editor in Chief
Neonatology Today

References
2. Campbell C. Comparing The Performance Of Two Pulse Oximeters And Electrocardiography During Neonatal Transition. neonatal INTENSIVE CARE Vol. 34 No. 2 n Spring 2021

Editor’s Correction: In Vol. 34, No. 3, Summer 2021 edition in the article Not All Donor Milk Is Equal, Table 2 incorrectly listed the temperature of vat pasteurization. The correct temperature is 66°C for 30 minutes.

Texas Hospital Delivers 107 Babies in 91 Hours
A Texas hospital set a record at the end of June when staff delivered more than 100 babies in 91 hours, according to a local report. The deliveries occurred across two 48-hour stretches at Andrew Women’s Hospital at Baylor Scott & White All Saints Medical Center in Fort Worth, according to WFAA 8, an ABC affiliate in Dallas. On June 24, staff delivered 25 girls and 27 boys in 47 hours. On June 28, staff delivered 55 babies, including a set of twin girls, in 44 hours. “It’s been all firework as our Labor and Delivery teams … have been busy delivering an adorable group of Fourth of July babies — 107 of them in just 91 hours to be exact!” the hospital said in a Facebook post. The stretch of deliveries broke the hospital’s record from June 2018, WFAA 8 reported. The hospital averages about 16 deliveries per day and last year delivered 6,000 babies, including 100 sets of twins and two sets of triplets. Six of the baby girls were named Gianna, the news outlet reported. Other popular names included Reign for girls and Atlas and Daniel for boys. The staff expected to see an uptick in births this year as people recover from the pandemic, but the June influx was rare and exceptional, according to NBC 5. “We thought it was going to be higher the last few months because of the pandemic, but didn’t see the baby boom until now, so people must’ve gotten more reassured,” Jay Herd, MD, an obstetrician at the hospital, told the news outlet. The hospital’s labor and delivery teams create photo galleries of babies who are born around the holidays. The Tiniest Texans series features portraits of the newborns, often dressed in holiday-themed clothes.

Fewer Preterm Infants in US Getting Mechanical Ventilation
The duration of respiratory support for preterm infants in the US has increased in recent years as the reliance on mechanical ventilation has declined and use of noninvasive ventilation has become more common, a new study suggests. Researchers examined data on preterm infants from a clinical cohort of 259,311 infants in the Pediatrix Clinical Data Warehouse as well as a national cohort of 1.17 million infants in the National Inpatient Sample. All the preterm infants were born before 35 weeks gestation and received care on neonatal intensive care.
units between 2008 and 2018. From 2008 to 2018, the proportion of neonates in the clinical cohort receiving mechanical ventilation declined from 29.4% to 18.5% and the proportion receiving noninvasive ventilation climbed from 57.9% to 67.4%. Over this same period, the mean number of days on respiratory support increased from 13.8 to 14.4, driven in large part by more widespread use of continuous positive airway pressure and nasal intermittent positive pressure ventilation, the study team reports in JAMA Pediatrics. “While our study couldn’t provide the exact reason why mechanical ventilation was decreasing, the decline in mechanical ventilation use seemed to begin at about the same time one of the largest clinical trials evaluating continuous positive airway pressure (CPAP) as the primary respiratory support in preterm infants was released,” said Dr. Dupree Hatch, an assistant professor of pediatrics and medical director of the NICU at Vanderbilt University Medical Center in Nashville, Tennessee, who led the current study.

“This study, the SUPPORT trial, along with several other studies released about the same time caused many of us in neonatal medicine to reconsider our approach to respiratory support in preterm infants,” Dr Hatch said by email. Over the study period, the mean duration of mechanical ventilation declined from 10.3 days to 9.7 days among infants who received this type of respiratory support. During the same period, the mean duration of noninvasive ventilation increased by 3.2 days among infants receiving this type of support. In the national cohort analysis, researchers also found evidence of reduced use of mechanical ventilation. The proportion of preterm infants receiving this form of respiratory support declined from 22.0% to 18.5% during the study period. One limitation of the analysis is that researchers were unable to link the two data sets, making it possible that the populations in the two cohorts might not be entirely comparable, the authors note. Changes in transfer patterns during the study period also could have influenced the outcomes. Even so, the results underscore the importance of clinicians keeping up to date on the literature around respiratory support and carefully considering how trial outcomes might be relevant in the treatment of individual patients, said Dr Sara DeMauro, associate director of neonatal clinical and epidemiological research at the Children’s Hospital of Philadelphia, who coauthored an editorial accompanying the study. “Mechanical ventilation usage is declining because neonatologists are concerned that exposure to mechanical ventilation is injurious, particularly to the preterm/immature lung,” Dr DeMauro said by email.

**Out-of-Pocket Costs for Childbirth More Than $3000**

Families with private health insurance pay around $3,000 for newborn delivery and hospitalization, while adding neonatal intensive care can push the bill closer to $5,000, based on a retrospective look at almost 400,000 episodes. The findings suggest that privately insured families need prenatal financial counseling, as well as screening for financial hardship after delivery, reported lead author Kao-Ping Chua, MD, PhD, assistant professor and health policy researcher in the department of pediatrics and the Susan B. Meister Child Health Evaluation and Research Center at the University of Michigan, Ann Arbor, and colleagues. “Concern is growing regarding the high and rising financial burden of childbirth for privately insured families,” the investigators wrote in Pediatrics. “Previous studies assessing this burden have focused on out-of-pocket spending for maternal care, including hospitalizations for delivery. However, there are no recent national data on out-of-pocket spending across the childbirth episode, including both deliveries and newborn hospitalizations.” To address this knowledge gap, Dr Chua and colleagues turned to Optum’s deidentified Clininformatics Data Mart, comprising 12 million privately insured individuals across the United States. The investigators identified 398,410 childbirth episodes occurring between 2016 and 2019. Each episode was defined as one delivery and at least one newborn hospitalization under the same family plan. Out-of-pocket cost included copayment plus coinsurance and deductibles. Primary outcomes included mean total out-of-pocket spending and proportion of episodes exceeding $5,000 or $10,000. Subgroup analyses compared differences in spending between episodes involving neonatal intensive care or cesarean birth. The mean out-of-pocket spending was $2,281 for delivery and $788 for newborn hospitalization, giving a total of $3,068 per childbirth episode. Coinsurance and deductibles accounted for much of that cost, at 55.8% and 42.1%, respectively, whereas copayments accounted for a relatively minor portion (2.2%). Almost all episodes (99%) cost more than zero dollars, while 17.1% cost more than $5,000 and 1.0% cost more than $10,000. Total mean out-of-pocket spending was higher for episodes involving cesarean birth ($83,389) or neonatal intensive care ($4,969), the latter of which cost more than $10,000 in 8.8% of episodes. “Because details on plan benefit design were unavailable, the generalizability of findings to all privately insured Americans is unclear,” the investigators noted. “However, the proportion of childbirth episodes covered by high-deductible health plans in this study is consistent with the prevalence of such plans among Americans with employer-sponsored insurance.” The findings suggest that financial reform is needed, Dr Chua and colleagues concluded. “To avoid imposing undue financial burden on families, private insurers should improve childbirth coverage,” they wrote. “An incremental step would be providing first-dollar coverage of deliveries and newborn hospitalizations before deductibles are met. Ideally, however, insurers would waive most or all cost-sharing for these hospitalizations, consistent with the approach taken by Medicaid programs and many developed countries.”

**Probiotic Supplementation Regulates Newborn Immune System**

Supplementing breastfed infants with bifidobacteria promotes development of a well-regulated immune system, theoretically reducing risk of immune-mediated conditions like allergies and asthma, according to investigators. These findings support the importance of early gut colonization with beneficial microbes, an event that may affect the immune system throughout life, reported lead author Bethany M. Henrick, PhD, director of immunology and diagnostics at Evolve Biosystems, Davis, Calif., and adjunct assistant professor at the University of Nebraska, Lincoln, and colleagues. “Dysbiosis of the infant gut microbiome is common in modern societies and a likely contributing factor to the increased incidences of immune-mediated disorders,” the investigators wrote in Cell. “Therefore, there is great interest in identifying microbial factors that can support healthier immune system imprinting and hopefully prevent cases of allergy, autoimmunity, and possibly other conditions involving the immune system.” Prevailing theory suggests that the rising incidence of neonatal intestinal dysbiosis—which is typical in developed countries—may be caused by a variety of factors, including cesarean sections; modern hygiene practices; antibiotics, antiseptics, and other medications; diets high in fat and sugar; and infant formula. According to Dr Henrick and colleagues, a healthy gut microbiome plays the greatest role in immunological development during the first 3 months post-partum; specifically, a lack of bifidobacteria during this
time has been linked with increased risks of autoimmunity and enteric inflammation, although underlying immune mechanisms remain unclear. Bifidobacteria also exemplify the symbiotic relationship between mothers, babies, and beneficial microbes. The investigators pointed out that breast milk contains human milk oligosaccharides (HMOs), which humans cannot digest, but are an excellent source of energy for bifidobacteria and other beneficial microbes, giving them a “selective nutritional advantage.” Bifidobacteria should therefore be common residents within the infant gut, but this is often not now the case, leading Dr Henrick and colleagues to zero in on the microbe, in hopes of determining the exactly how beneficial bacteria shape immune development. It is only recently that the necessary knowledge and techniques to perform studies like this one have become available, the investigators wrote, noting a better understanding of cell-regulatory relationships, advances in immune profiling at the systems level, and new technology that allows for profiling small-volume samples from infants. The present study involved a series of observational experiments and a small interventional trial. First, the investigators conducted a wide array of blood- and fecal-based longitudinal analyses from 208 infants in Sweden to characterize immune cell expansion and microbiome colonization of the gut, with a focus on bifidobacteria. Their results showed that infants lacking bifidobacteria, and HMO-utilization genes (which are expressed by bifidobacteria and other beneficial microbes), had higher levels of systemic inflammation, including increased T helper 2 (Th2) and Th17 responses. "Infants not colonized by Bifidobacteriaceae or in cases where these microbes fail to expand during the first months of life there is evidence of systemic and intestinal inflammation, increased frequencies of activated immune cells, and reduced levels of regulatory cells indicative of systemic immune dysregulation," the investigators wrote. The interventional part of the study involved 60 breastfed infants in California. Twenty-nine of the newborns were given 1.8 × 1010 colony-forming units (CFUs) of B. longum subsp. infantis EVC001 daily from postnatal day 7 to day 28, while the remaining 31 infants were given no supplementation. Fecal samples were collected on day 6 and day 60. At day 60, supplemented infants had high levels of HMO-utilization genes, plus significantly greater alpha diversity (P = .0001; Wilcoxon), compared with controls. Infants receiving EVC001 also had less inflammatory fecal cytokines, suggesting that microbes expressing HMO-utilization genes cause a shift away from proinflammatory Th2 and Th17 responses, and toward Th1.

Company Signs Agreement with University
Neotech Products has entered into a mutually beneficial agreement with Wichita State University. This exciting collaboration will provide Neotech with the resources of an institution well known for advanced research, including clinical work through their partners. Wichita State, a national leader in aerospace research, will benefit from the experience of a well-established and innovative medical device company as it expands research in the area of medical products. They will work closely with Neotech's new product development team to explore product ideas that will impact the end user. "Wichita State is committed to using our aviation expertise for expanding research in other industries," said Rick Muma, President of Wichita State University. "As a clinician in internal medicine and infectious diseases and a public health practitioner, I understand the need to continually innovate through collaboration in the healthcare sector. Partnerships
with companies like Neotech Products do just that." With this partnership, Neotech will have access to advanced facilities and technologies, including: Labs for materials and adhesive testing and research; Electron microscopes; CT scanning (for materials); Pull and compression testing; A wide array of 3D printing and scanning; VR visual design space. The partnerships’ first collaboration is a locking mechanism for the NeoBar ET Tube Holder. The idea originated with Dr Mohammed Ansari, a neonatologist with ties to the Wichita area. Wichita State teamed up with Dr Ansari and brought the idea to Neotech to drive the project forward. We’re extremely excited to see where it leads. Overall, the purpose of the partnership between Neotech and Wichita State is to utilize the combined expertise of both institutions to bring medical products to market that will truly make a difference.

**Mother-to-Infant COVID-19 Transmission Is Unlikely**

Mothers with a history of COVID-19 exposure during pregnancy are not likely to transmit the infection to their newborns, based on data from more than 2,000 women. “Uncertainty at the onset of the COVID-19 pandemic led to varying postnatal care recommendations for newborns exposed to SARS-CoV-2 in utero,” said Margaret H. Kyle, of Columbia University, New York, and colleagues. The Columbia University Irving Medical Center, an early epicenter of the pandemic, allowed rooming-in and encouraged direct breastfeeding between infected mothers and their newborns while adopting extensive safety measures, the researchers said. In a study presented at the virtual meeting of the Pediatric Academic Societies, the researchers conducted a retrospective chart review of all newborns born at the medical center from March 22, 2020, through August 7, 2020. The study was part of Columbia University's ongoing COVID-19 Mother Baby Outcomes (COMBO) initiative to “describe the health and well-being of mother-infant dyads with and without prenatal SARS-CoV-2 infections,” according to the researchers. During the study period, the researchers identified newborns of 327 women who tested positive for COVID-19 at any point during pregnancy and compared them to newborns of 2,125 unexposed women. Demographics were similar between the groups. Overall, the total test positivity was 0.7% for exposed newborns; 1.0% tested positive on an initial test, and 0% were positive on retest. During the newborn hospital stay and a 2-week follow-up, 0% of all newborns showed clinical evidence of infection. No significant differences were noted between exposed and unexposed newborns in clinical outcomes including gestational age, mode of delivery, 5-minute Apgar score, heart rate, respiratory rate, or temperature. Although more infants of COVID-19-exposed mothers compared with unexposed mothers had an emergency department visit within the first 14 days of life (6% vs. 3%, P = .002), none of the infants was diagnosed with COVID-19 during these visits. Cough, fever, congestion, or bilirubin were more frequent reasons for emergency department visits in the exposed infants compared with unexposed infants, but these differences were not significant. The study findings were limited by several factors, including the retrospective design and the limited follow-up period to only the first 2 weeks of life, the researchers noted. In addition, perinatal transmission rates were available only for the 202 newborns who were followed up in the hospital system, they said. However, the results suggest that the risk of mother-to-newborn vertical transmission of COVID-19 remains low, even when mothers are breastfeeding and infants are rooming in, they concluded.

**Skip Routine Probiotics for Preemies, AAP Says**

The American Academy of Pediatrics (AAP) now recommends against the routine administration of probiotics to preterm infants, particularly the most vulnerable (those whose birth weight is <1000 g), for the treatment or prevention of necrotizing enterocolitis (NEC) and late-onset sepsis. Although probiotics are increasingly given to preterm infants, the AAP notes that the data on their safety and efficacy are inconsistent. In addition, the supplements are not subject to approval by the US Food and Drug Administration (FDA). Therefore, the academy advises clinicians to use extreme caution in selecting preterm neonates to receive these microorganisms and recommends obtaining informed consent from parents after carefully discussing the risks. It also recommends that centers using probiotics conduct surveillance, inasmuch as probiotics can alter a center’s flora, potentially affecting all patients. Such centers should also carefully document outcomes, adverse events, and safety. The AAP’s clinical report, published online May 24 in Pediatrics, highlights wide differences between commercially available formulations and a lack of regulatory standards in this country. Absent FDA-approved drug labeling, these nutritional supplements cannot be marketed as treatment or prophylaxis, but that has scarcely stopped their use. “Despite lack of availability of a pharmaceutical-grade product, the number of preterm infants receiving probiotics in the United States and Canada is steadily increasing,” write Brenda Poindexter, MD, FAAP, chief of neonatology at Children’s Healthcare of Atlanta, in Atlanta, Georgia, and members of the AAP's Committee on Fetus and Newborn. Analyses of US collaborative databases indicate that approximately 10% of neonates of extremely low gestational age receive a probiotic preparation in the neonatal intensive care unit (NICU). The use of these preparations varies widely across
institutions. “NEC is a devastating morbidity of prematurity, and it's multifactorial. Some babies only given mother's milk still get NEC, and the decision to use these products is a very nuanced one,” Poindexter said. “I suspect some people will disagree with the report, and we tried to give folks some wiggle room.” Evidence from other countries suggests that probiotics can be protective against NEC, she added, “so not to have a reliable product in this country is very frustrating.”

**Guidance Reviewed on ‘Kangaroo Care’**

When a baby is born prematurely, immediate skin-to-skin contact could save their lives. Instead of placing low-weight newborns in an incubator, new research suggests they should be nestled up close to their mother’s chest, or that of a close caregiver’s, and fed exclusively on breast milk. This approach, dubbed kangaroo care, has proved to be one of the best and safest ways to treat preterm infants with low birth weights, resulting in fewer infections, higher rates of breastfeeding, and better weight gain in studies. Despite the growing number of benefits, the practice has not been widely adopted. Currently, the World Health Organization recommends continuous kangaroo care for all preterm infants, but only after they are taken away and declared clinically stable in the neonatal intensive care unit (NICU). A randomized controlled trial in five hospitals now suggests the WHO’s recommendation separates babies and their mothers too soon. Instead, hospitals should implement a mother-infant care unit with beds and chairs so that hospital staff can look after new parents and babies at the same time. The study was conducted among 3,211 low-weight infants in Ghana, India, Malawi, Nigeria, and Tanzania, who were either assigned immediate kangaroo care in a specially arranged “Mother-NICU” or were separated from the parents for conventional care, with brief moments of touch allowed after the first 24 hours. In the first three days, infants who received immediate skin-to-skin contact were held for roughly 17 hours a day in the Mother-NICU. Meanwhile, those infants placed in incubators or radiant warmers received only 1.5 hours of intermittent daily contact. Compared to conventional neonatal care, those infants who received immediate touch from their parents were 25 percent less likely to die in the first month of life. Continuously held newborns were also less likely to develop hypothermia and bacterial blood poisoning, possibly because these infants had greater exposure to their mother’s protective microbiome, were more likely to receive early breast milk, and were handled by fewer people. Avoiding separation stress between the mother and the infant might also have contributed to greater health outcomes. Touch between a baby and its mother has been shown to stabilize the newborn’s heart rate, calm its breathing, and decrease its crying. “Keeping the mother and baby together right from birth, with zero separation, will revolutionize the way neonatal intensive care is practiced for babies born early or small,” argues Rajiv Bahl, the Head of Maternal and Newborn Health Research and Development at WHO. “This study illustrates that kangaroo mother care has the potential to save many more lives if it is started immediately after birth, a finding with relevance for countries of all income levels.” Today, over 96 percent of all infants with a low birth weight are born in developing countries, and these children are particularly vulnerable to infectious disease, developmental delays, and death. Conventional neonatal care is expensive and requires great skill and logistical support, which many countries with lower incomes cannot afford. Kangaroo care, on the other hand, is a safe and effective alternative much easier to implement. The
Comprehensive Solution For Nitric Oxide Inhalation Therapy

Complete with 24/7/365 support – peace of mind for critical care providers.

National Reach, Local Service

NOXIVENT® (nitric oxide) gas for inhalation, along with the NOxBOXi® delivery system, offered with customizable, consumption-based billing, is backed by Linde’s national network, responsive support and reputation for medical gas distribution.

The NOxBOXi nitric oxide gas delivery system is reliable, accurate and easy to use. System features include:

- Real-time, closed-loop monitoring with auto-adjusting alarms
- Pre-packaged, configured circuits ready for use with validated ventilators
- Disposable circuits, including the NOxFLOW module, for easy clean up
- Auto-cylinder changeover with alerts, helping you avoid therapy interruptions

Our Commitment

- Integrated gas delivery system for inhaled nitric oxide therapy
- 24/7/365 service and support
- Simplified billing process
- Reliable and responsive distribution network
- Established reputation for quality and customer satisfaction

A summary of the prescribing information, including indication and other important safety information, is on the adjacent page. For the full prescribing information, visit www.noxiventus.com.

Call 1-844-445-4633 today for a complimentary requirements evaluation.
www.noxiventus.com
NOXIVENT® Indication and Important Safety Information

Indication

Noxivent® is a vasodilator indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

Important Safety Information

Contraindications

Noxivent is contraindicated in neonates dependent on right-to-left shunting of blood.

Warnings and Precautions

Rebound: Abrupt discontinuation of Noxivent may lead to worsening oxygenation and increasing pulmonary artery pressure.

Methemoglobinemia: Methemoglobin levels increase with the dose of Noxivent; it can take 8 hours or more before steadystate methemoglobin levels are attained. If methemoglobin levels do not resolve with decrease in dose or discontinuation of Noxivent, additional therapy may be warranted to treat methemoglobinemia.

Airway Injury from Nitrogen Dioxide: Monitor nitrogen dioxide (NO2) levels. Nitrogen dioxide may cause airway inflammation and damage to lung tissue.

Heart Failure: In patients with pre-existing left ventricular dysfunction, Noxivent may increase pulmonary capillary wedge pressure leading to pulmonary edema.

Adverse Reactions

The most common adverse reaction of Noxivent is hypotension.

Drug Interactions

Nitric Oxide donor compounds may increase the risk of developing methemoglobinemia.

Administration

Use only with a calibrated, FDA-cleared NOxBOXi® Nitric Oxide Delivery System (NODS). Refer to the NODS labeling for needed information on training and technical support for users of this drug product with the NODS.

Please see the full Prescribing Information for additional important Noxivent® safety and risk information.
findings support a recent meta-analysis that found kangaroo care after clinical stabilization results in 40 percent lower infant mortality. Yet, many premature babies don’t make it to that stage. Studies reveal nearly 50 percent of neonatal deaths in a number of Asian and African nations occur within 24 hours of delivery, and 80 percent occur in the first week of life, which means many lives are being lost before kangaroo care can be initiated. “The idea of giving skin-to-skin contact immediately after delivery to very small, unstable babies has encountered quite strong resistance, but about 75 percent of deaths occur before the infant has been judged sufficiently stable,” explains Nils Bergman from the Karolinska Institutet in Sweden. If low-weight infants receive immediate kangaroo care, the authors of the new study estimate it could save 150,000 underweight newborns each year. WHO is currently in the process of reviewing its guidance on kangaroo care.

**Vaping and Pregnancy: Inhaled Toxins Among Reasons for Pause**

Researchers are trying to understand how e-cigarette use affects pregnancy and birth outcomes. This question may become more relevant as younger vapers, among whom the devices gained considerable popularity, start having children. Limited emerging data from animal experiments and human epidemiologic studies suggest that vaping may have negative effects on fertility and pregnancy. “Even if these impacts are less severe than conventional smoking, we really should be thinking about alternate options that may be safer for our patients than inhalation of this aerosol,” said Blair J Wylie, MD, MPH, a maternal-fetal medicine physician at Beth Israel Deaconess Medical Center in Boston. Wylie reviewed what is known about vaping, including chemicals other than nicotine that have been detected in vape aerosols, and pregnancy at the 2021 virtual meeting of the American College of Obstetricians and Gynecologists. “There’s a lot we don’t know,” she said. “These products were only introduced recently, in 2003. They are marketed aggressively to our youth and have gained tremendous popularity among that population. And it’s only a matter of time, I think, before we see a lot of use in our own patient population.”

In a separate study presented at the ACOG meeting, Nicole Izhakoff, a researcher at Florida International University, Miami, and colleagues evaluated the association between e-cigarette use during pregnancy and unfavorable birth outcomes, such as preterm birth, low birth weight, or extended hospital stay for the newborn. The investigators used 2016-2017 survey data from the Pregnancy Risk Assessment Monitoring System. In all, 71,940 women completed the survey, including 859 who reported e-cigarette use during pregnancy. After adjusting for age, race, ethnicity, insurance, maternal education, prenatal care, abuse during pregnancy, and complications during pregnancy, the researchers estimated that the odds of an unfavorable birth outcome were 62% greater among women who used e-cigarettes during pregnancy, compared with those who did not. The researchers lacked information about simultaneous use of alcohol, traditional tobacco, or other drugs, however. “Physicians of all subspecialties, especially those of obstetrics-gynecology and pediatrics, need to increase the implementation of screening for past or current e-cigarette use in at-risk patients,” Ms Izhakoff and coauthors concluded. “Further research regarding the long-term health effects of e-cigarettes is warranted.” Wylie coauthored another study related to this topic that was published online May 24, 2021, in the Journal of Maternal-Fetal & Neonatal Medicine. The researchers examined birth weights of children whose mothers use e-cigarettes alone, those whose mothers used both e-cigarettes and conventional cigarettes, and those whose mothers smoked conventional cigarettes only. Their estimates were imprecise, but signaled that e-cigarette use may reduce birth weight. The use of e-cigarettes alone appeared to have less of an impact on birth weight than the dual use of conventional cigarettes and e-cigarettes did. Wylie cautioned that outcomes like birth weight are “pretty crude measures of whether an exposure is okay or not in pregnancy. Many of these toxins that we know that are in the aerosols can cause harm, but they may not be reflected in the absolute value of the birth weight.” In addition, clinicians should avoid focusing on the wrong question when caring for patients. “I think the wrong question is: Is vaping safer than smoking?” Wylie said in an interview. “Metals are going into your lungs. Plastics are going into your lungs. It is hard for me to think that we are going to identify that as our champion smoking cessation strategy in pregnancy.”

**Children Born Just Weeks Early Face Higher Risk of Developmental Problems**

Children born preterm (before 37 weeks of pregnancy) remain at high risk of developmental difficulties that can affect their behaviour and ability to learn, finds a study published by The BMJ today. These difficulties were found not only in children born extremely preterm (22-26 weeks) but also in those born very and moderately preterm (between 27 and 34 weeks), say researchers. Survival of preterm babies has increased worldwide. Children born early often have developmental issues, but studies have mainly focused on those born extremely preterm (22-26 weeks’ gestation) and less is known about children born very and moderately preterm (27-34 weeks’ gestation). Given how important it is to identify children most at risk of developmental difficulties, researchers in France set out to describe neurodevelopment among children born before 35 weeks compared with children born at full term. Their findings are based on 3,083 French children aged 5½ born after 24-26, 27-31, and 32-34 weeks gestation who were taking part in the EPIPAGE-2 study (designed to investigate outcomes of preterm children over the past 15 years) and a comparison group of 600 children born at full term. Neurodevelopmental outcomes such as cerebral palsy, sensory impairments (blindness and deafness), and brain function (cognition), as well as behavioural difficulties and movement disorders, were assessed using recognised tests. To further assess the family and social burden of prematurity, measures such as the need for extra support at school, visits to a psychiatrist, speech therapist or physiotherapist, and parental concerns about development, were also recorded. After adjusting for other potentially influential factors, the researchers found that rates of neurodevelopmental disabilities increased as gestational age decreased. For example, among the 3,083 children assessed, rates of severe to moderate neurodevelopmental disabilities were 28%, 19% and 12% and rates of mild disabilities were 39%, 36%, and 34% among children born at 24-26, 27-31 and 32-34 weeks, respectively. Assistance at school was used by 27%, 14% and 7% of children born at 24-26, 27-31, and 32-34 weeks, respectively. And about half of children born at 24-26 weeks received at least one developmental intervention which fell to 26% for those born at 32-34 weeks. Behaviour was the concern most commonly reported by parents. Rates of neurodevelopmental disabilities were also higher in families with low socioeconomic status. This is an observational study, so can’t establish cause, and the researchers point to some limitations that may have affected their results. However, by assessing a wide range of developmental and behavioural issues, they were better able to reflect the complexity of difficulties.
faced by these children and their families. As such, they say their findings indicate that preterm birth “continues to pose a large burden for families, healthcare, and educational systems.” Although rates of severe to moderate neurodevelopmental disabilities decreased with increasing gestational age, they point out that around 35% of the moderately to extremely preterm born children had mild disabilities requiring special care or educational services. And a considerable proportion of parents had concerns about their child’s development, particularly about behaviour, which warrant attention, they add. “Difficulties faced by these groups of children and their families should not be underestimated,” they conclude.

Stopping Seizure Meds Before Hospital Discharge Appears Safe in Most Newborns
Researchers observed no difference in functional neurodevelopment or epilepsy among children aged 24 months regardless of whether antiseizure medication was discontinued or maintained in infants at discharge once seizures ceased. Results of the comparative effectiveness study were published in JAMA Neurology. “These results support discontinuing antiseizure medications (ASMs) for most neonates with acute symptomatic seizures prior to discharge from the hospital, an approach that may represent an evidence-based change in practice for many clinicians,” Hannah C. Glass, MDCM, MAS, a pediatric neurologist, founding codirector of the neurointensive care nursery and director of neonatal critical care services at the University of California, San Francisco Benioff Children’s Hospital, and colleagues wrote. ASMs can be maintained in infants for months or years unnecessarily, according to the researchers, due to concerns over continued seizures and early-life epilepsy. Glass and colleagues investigated the impact of early discontinuation of ASM after acute symptomatic neonatal seizures resolved but prior to hospital discharge on functional neurodevelopment and risk for epilepsy at 24 months of age. This prospective, observational, multicenter comparative effectiveness study enrolled 303 infants with acute symptomatic neonatal seizures who were born between July 2015 and March 2018 and enrolled at nine Neonatal Seizure Registry centers with level IV neonatal ICUs and pediatric epilepsy programs. The study included slightly more male infants (56%) than female infants. Glass and colleagues continuously monitored infants using a conventional electroencephalogram. Dosing and treatment were employed under the advisement of local health care professionals. The researchers collected data on ASM type, discontinuation or maintenance and timing and dosage of medication. The researchers also analyzed demographic, clinical and primary seizure causation factors. Parents of the infants reported neurodevelopmental outcomes at 12, 18 and 24 months, corroborated by a medical record review. The primary outcome of the study was functional neurodevelopment at 24 months, which Glass and colleagues measured using the Warner Initial Development Evaluation of Adaptive and Functional Skills questionnaire (WIDEA-FS). Among the 303 infants, 43% of seizures was caused by hypoxic-ischemic encephalopathy, 26% by ischemic stroke, 18% by intracranial hemorrhage and the remaining 13% by another acute brain injury. The local health care professionals prescribed phenobarbital as the first loading ASM in 90% of infants. Upon discharge, a majority (64%) of patients were maintained on ASMs (P < .001). ASM maintenance occurred more often in infants with high seizure

Continued on page 18...
Near-Infrared Spectroscopy, or NIRS, is a non-invasive technology that continuously monitors regional tissue oxygenation ($rSO_2$). Originally used for the assessment of oxygen saturation of the brain, use has now been expanded to the evaluation of other organs and tissues.\(^1\)

In neonates, particularly the premature population, NIRS can be used to manage the delicate shifts and clinical interventions associated with hemodynamic and ventilation stability by monitoring changes in trends over time.\(^2\) Each tissue bed will have varying degrees of oxygen extraction, depending on the metabolic needs.\(^3\)

With prematurity comes immature suboptimal functioning organs, placing these organs at risk for inefficient oxygen exchange and perfusion. Routine vital signs monitoring assesses more global measures of oxygen exchange and may be inadequate for capturing oxygen supply, demand, or content at the organ level. Despite the clinical benefits, NIRS has been underutilized in the NICU population.

Continuous, reliable, and real-time assessment of the cardiovascular function in preterm and term neonates has long been elusive in neonatal medicine despite being available for 20 years. Despite the availability and the use of NIRS as a surrogate to other vital and clinical signs, such as cardiac output (CO) and systemic vascular resistance (SVR), organ flow distribution and tissue oxygen delivery has only recently been explored. In routine clinical care, we rely on the information obtained from blood pressure monitoring but cannot routinely assess changes in cardiac output and/or systemic vascular resistance when hypotension and cardiovascular compromise are diagnosed and treated.\(^4-5\) One of the primary roles of cardiovascular circulation is to ensure adequate delivery of oxygen and nutrients to the cell so that their metabolism demand is met.

Maintenance of oxygen demand to oxygen delivery is essential for normal organ function and integrity.\(^6-7\) This process is important in the developing brain of very preterm neonates because the vessels of the forebrain do not function as high-priority vessels at birth. In these neonates, the vasculature of the forebrain responds to stress and decreases in perfusion pressure by vasoconstriction even as BP remains in the perceived normal range. The oxygen demand cannot be satisfied by changes in local blood flow. This is accomplished by secondary mechanisms of oxygen demand-deliver coupling (blow flow and oxygen extraction) such as increasing tissue oxygen extraction and recruitment of more capillaries.\(^8-10\)

NIRS can be used to monitor some of the mechanisms of oxygen demand-delivery coupling. A multisite NIRS approach, for monitoring other organs and tissues in addition to the brain for hemodynamic assessment, has shown a good correlation with venous oxygen saturation. The two-site model shows that perirenal $rSO_2$ is more sensitive to circulation changes than cerebral $rSO_2$.\(^11\) Multisite NIRS monitoring might help in the detection of low tissue oxygen delivery that may lead to adverse outcomes.\(^12\)

In the absence of non-invasively and continuously monitored measures of systemic blood flow, clinicians have used non-specific indirect measures of systemic blood flow and tissue perfusion including urine output, capillary refill time, peripheral-core temperature differences, and serum lactate levels. These indirect signs have limitations and can be late indicators of decompensation compared to NIRS.
Cerebral injury acquired in the neonatal period can have an impact on the quality of life for both the neonate and their family. Disturbances in cerebral perfusion and oxygenation can contribute to brain injury in neonates born preterm and can contribute to impaired neurodevelopmental outcomes.13,15

A non-invasive approach to the continuous monitoring of oxygen supply and utilization can be helpful for the management of sick neonates admitted to the NICU. Both pulse oximetry and NIRS have accepted methodologies for monitoring arterial and regional tissue oxygenation.16 Watkin et al. reported high sensitivity of NIRS-detected variables of cerebral oxygenation to hypoxemic and ischemic events occurring in preterm infants.17 In one study the results showed most mechanically ventilated preterm neonates with a decreased arterial saturation of 70–80% did not have significantly compromised oxygen utilization in the cerebral tissue but increased oxygen extraction in the peri-renal tissue. This may cause ischemic tissue injury following a further reduction in oxygen delivery.18 To maintain adequate oxygen utilization during the desaturation episodes, the decreased oxygen delivery to the renal tissue is initially compensated by increased oxygen extraction.

Dix et al. showed that an acute increase in End Tidal CO$_2$ ($\text{etCO}_2$) is associated with increased cerebral oxygenation and decreased brain activity, and an acute decrease in $\text{etCO}_2$ is associated with decreased cerebral oxygenation and slightly increased brain activity.19 The study also noted, using $\text{etCO}_2$ and NIRS monitoring may help detect fluctuations in arterial carbon dioxide partial pressure (pCO$_2$) which could be harmful to the neonatal brain.20,21 The etCO$_2$ was used as a surrogate marker for arterial pCO$_2$ or the gold standard in neonatal care to assess ventilation efficiency.19 However, etCO$_2$ monitoring may not be suitable for all patients due to the questionable accuracy in the presence of low tidal volumes.21

Another consideration is how carbon dioxide impacts vasodilation and constriction. Hypercapnia induces vasodilation and hypocapnia induces vasoconstriction of the cerebral arterial blood vessels in newborn infants. The brain of a preterm infant is susceptible to disturbances in flow because of the relatively immature cerebral vascularization and limited autoregulatory capability.22 In the Dix et al. study, fluctuation in pCO$_2$, even within the normal range, appear to affect neonatal cerebral oxygenation and electrical activity. The authors noted that clinicians should be aware of these effects and evaluate the benefits of continuous CO$_2$ monitoring used with NIRS and EEG to identify and limit the effects of CO$_2$ fluctuations.19

Summary: The premature neonate or the sickest of infants are at risk of injury to vital organs and can contribute to neonatal mortality and morbidity. A state of hypoxia and hyperoxia in the cerebral and other tissues can lead to adverse outcomes. The use of NIRS monitoring can assist in hemodynamic and ventilation management by providing a real-time measure of oxygen saturation in the tissues. Having a window into the effect of clinical interventions, objective data, and real-time changes in the physiology of the tissue bed of concern, the clinician can respond quickly and effectively leading to positive outcomes with a first alert to changes in perfusion before changes are seen in vital signs or other data collection.23

References
19 Dix, LML, Weeke, LC, de Cries, LS, et al. Carbon Dioxide


News...continued from page 15

burdens, complex clinical courses and abnormal neurological findings at time of discharge. The median treatment length on ASMs in infants with maintained ASMs was 4 months compared with 6 days among those whose medication was discontinued. In the 270 children who returned at 24 months of age for follow-up, the median WIDEA-FS score was 164, with slightly higher scoring (+4 points; 2%) in children whose medication was discontinued prior to a hospital discharge (37%). However, the researchers observed no difference between the two cohorts with regard to functional neurodevelopment or epilepsy at 24 months. "Our findings suggest that staying on antiseizure medication after leaving the hospital doesn’t protect babies from continued seizures or prevent epilepsy and it does not change developmental outcomes," Glass said in a press release. “Most of the babies in this study went home on antiseizure medications, which suggests we need to re-think standard practice. We’ve never had such robust data from multiple centers to support this type of change for newborns with seizures.”
The Risk of Mortality for Patients with Persistently Elevated HeRO Scores

William E King, MS

Background
The HeRO index, or HeRO Score, was developed to predict imminent infection among premature infants by detecting abnormal heart rate variability (HRV) that is associated with pro-inflammatory cytokines. Elevated HeRO Scores have been linked with a number of adverse events in neonates, including death. The clinical utility of HeRO monitoring was assessed in a pragmatic randomized controlled trial of 3,003 very low birthweight (VLBW; birth weight < 1500g) patients, the largest ever conducted among premature infants. Randomization to have HeRO Scores displayed to clinicians was associated with an all-cause mortality reduction of 22%, and a reduction in mortality after infection of 40%.

As more neonatal ICUs around the world adopt HeRO monitoring in their units, clinicians have observed patients with persistently elevated HeRO Scores. That is, a HeRO Score that stays at the maximum value that HeRO will display, 7.0, for several days at a time. In this analysis, we sought to use the control patients (i.e., those randomized to HeRO non-display) from the RCT dataset to discern the implications of persistently elevated HeRO Scores on mortality.

Methods
For each hourly HeRO Score generated by control patients (those randomized to have HeRO Scores masked from clinicians) in the RCT dataset, we calculated the median HeRO Score of the previous 7-day period whenever there was at least 75% data coverage (that is, at least 168 x 75% = 126 hourly HeRO Scores were available in the previous seven days). For each patient, we took the maximum value of each of these 7-day medians, and called it the maximum 7-day median HeRO Score.

We defined a patient as having had a persistently elevated HeRO Score when the maximum 7-day median HeRO Score was 7.0 (the highest possible). It is important to note that the patient must have survived at least 126 hours in order to have a maximum 7-day median HeRO Score.

Patients without a complete pertinent demographic record or without a maximum 7-day median HeRO Score were excluded from subsequent analysis. We compared the rate of mortality among those patients with a persistently elevated HeRO Score to those without.

Results
Of the 1488 control patients in the RCT, 1266 patients had complete demographics records and enough HeRO Scores to be included in this analysis. The overall mortality was 7.5% in this cohort. Table 1 shows the demographic characteristics of those patients with and without a persistently elevated HeRO Score (maximum 7-day median HeRO Score = 7.0). 7.4% of patients had a persistently elevated HeRO Score, and their mortality was 7x those without (37.2% versus 5.1%, respectively, p<0.0001).

Table 2 shows metrics of the maximum 7-day median HeRO Score to predict death for a number of thresholds. ROC was 0.865 (95% CI: 0.832 to 0.898).

Further, we calculated the performance of the maximum 7-day median HeRO Score as a predictor of death using standard metrics (Sensitivity, Specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV), Risk Ratio, and area under the Receiver Operating Characteristic (ROC) curve) at a variety of thresholds besides 7.0.

We used a logistic regression model to evaluate the performance of available demographics variables that were collected during the RCT to predict mortality, and compared it to a logistic regression model using the same demographic variables plus maximum 7-day median HeRO Score.

Finally, we repeated all analyses using the mean 7-day HeRO rather than the median.

All calculations were performed in R. We assessed significance at p<0.05.

Figure 1. A patient with a persistently elevated HeRO Score. The plot is showing a 5-day trend of the hourly HeRO Score on the left as well as the most recent hourly HeRO Score on the right.

Figure 1. A patient with a persistently elevated HeRO Score. The plot is showing a 5-day trend of the hourly HeRO Score on the left as well as the most recent hourly HeRO Score on the right.

Figure 1. A patient with a persistently elevated HeRO Score. The plot is showing a 5-day trend of the hourly HeRO Score on the left as well as the most recent hourly HeRO Score on the right.

Figure 1. A patient with a persistently elevated HeRO Score. The plot is showing a 5-day trend of the hourly HeRO Score on the left as well as the most recent hourly HeRO Score on the right.

Figure 1. A patient with a persistently elevated HeRO Score. The plot is showing a 5-day trend of the hourly HeRO Score on the left as well as the most recent hourly HeRO Score on the right.

Figure 1. A patient with a persistently elevated HeRO Score. The plot is showing a 5-day trend of the hourly HeRO Score on the left as well as the most recent hourly HeRO Score on the right.
persistently elevated HeRO Scores. We found that those patients with a maximum 7-day median HeRO Score of 7 or more had a profound risk of death when compared to other patients (37.2% versus 5.1%, respectively).

Furthermore, we found that patients with low maximum 7-day median HeRO Scores had remarkably low rates of death. For the 35% of patients for whom the maximum 7-day median HeRO Score fell below 1.0, survival was 99.8%, and these patients are more than 50x less likely to die than other patients. The mean HeRO Score over the previous 7 days appeared to have even better performance because it was able to capture late spikes in HeRO prior to death better than the median over the previous seven days. Essentially, patients did not die without elevations in their HeRO Scores.

These results remained true when controlling for demographic predictors.

Weaknesses of the current analysis are its retrospective nature and lack of a complete set of demographic predictors. A strength is that it is a large dataset of patients for whom the HeRO Score was generated but not displayed to clinicians, eliminating a potential feedback loop of scores affecting outcomes.

Table 1. Patient Demographics. Continuous variables were evaluated with a t-test, categorical variables were evaluated with a test of proportions.

<table>
<thead>
<tr>
<th></th>
<th>No Persistently Elevated HeRO Score</th>
<th>Persistently Elevated HeRO Score</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>N (% of total)</td>
<td>1172 (92.6%)</td>
<td>94 (7.4%)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Gestational Age (sd)</td>
<td>28.3 (2.7)</td>
<td>25.2 (1.5)</td>
<td></td>
</tr>
<tr>
<td>Birth Weight (sd)</td>
<td>1018 (282)</td>
<td>724 (184)</td>
<td></td>
</tr>
<tr>
<td>Male Sex (%)</td>
<td>601 (51.3%)</td>
<td>47 (50%)</td>
<td>0.895</td>
</tr>
<tr>
<td>Apgar 1 (sd)</td>
<td>5.2 (2.5)</td>
<td>3.2 (2.2)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Apgar 2 (sd)</td>
<td>7.2 (1.8)</td>
<td>5.7 (2.0)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Died (%)</td>
<td>60 (5.1%)</td>
<td>35 (37.2%)</td>
<td>&lt; 0.0001</td>
</tr>
</tbody>
</table>

Table 2. Metrics of various thresholds of maximum 7-day median HeRO Score to predict death.

<table>
<thead>
<tr>
<th>HeRO Threshold</th>
<th>Percentile</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>PPV</th>
<th>NPV</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>35.4\text{th}</td>
<td>98.9%</td>
<td>38.3%</td>
<td>11.5%</td>
<td>99.8%</td>
<td>51.7x</td>
</tr>
<tr>
<td>2.0</td>
<td>58.8\text{th}</td>
<td>93.7%</td>
<td>63.1%</td>
<td>17.1%</td>
<td>99.2%</td>
<td>21.2x</td>
</tr>
<tr>
<td>5.0</td>
<td>85.0\text{th}</td>
<td>62.1%</td>
<td>88.8%</td>
<td>31.1%</td>
<td>96.7%</td>
<td>9.3x</td>
</tr>
<tr>
<td>7.0</td>
<td>92.6\text{th}</td>
<td>36.8%</td>
<td>95.0%</td>
<td>37.2%</td>
<td>94.9%</td>
<td>7.3x</td>
</tr>
</tbody>
</table>

Performance using maximum 7-day mean HeRO Score was slightly improved relative to the median. ROC of the maximum 7-day mean HeRO Score was 0.871 (95% CI: 0.840 to 0.903) versus 0.865 for the median. Remarkably, the risk ratio of death for those above the 50\text{th} percentile versus below the 50\text{th} percentile of the demographics plus maximum 7-day mean HeRO Score model was 92x, versus 46x for same model using the median.

Discussion

The randomized controlled trial of HeRO monitoring was a pragmatic design. That is, clinicians were not instructed to perform specific clinical actions at set thresholds of HeRO Score. Instead, they were educated on how the HeRO Score was developed and left to incorporate HeRO into their clinical practice as they saw fit.

An advantage of this pragmatic design is that the profoundly positive results of the RCT should be reproducible in clinical practice outside the rigors of an RCT protocol. Nevertheless, clinicians are left without concrete direction as to what thresholds of HeRO Score are actionable.

Of utmost difficulty for the practicing neonatologist is a patient with persistently elevated HeRO Scores. Although the numeric value is high, there is no discernible trend to guide the clinician that this patient is trending “better” or “worse”.

In the present analysis, we have re-analyzed control patients in the HeRO randomized controlled trial to identify patients with persistently elevated HeRO Scores. We found that those patients with a maximum 7-day median HeRO Score of 7 or more had a profound risk of death when compared to other patients (37.2% versus 5.1%, respectively).

Furthermore, we found that patients with low maximum 7-day median HeRO Scores had remarkable low rates of death. For the 35% of patients for whom the maximum 7-day median HeRO Score fell below 1.0, survival was 99.8%, and these patients are more than 50x less likely to die than other patients. The mean HeRO Score over the previous 7 days appeared to have even better performance because it was able to capture late spikes in HeRO prior to death better than the median over the previous seven days. Essentially, patients did not die without elevations in their HeRO Scores.

These results remained true when controlling for demographic predictors.

Weaknesses of the current analysis are its retrospective nature and lack of a complete set of demographic predictors. A strength is that it is a large dataset of patients for whom the HeRO Score was generated but not displayed to clinicians, eliminating a potential feedback loop of scores affecting outcomes.
Conclusion
Clinicians should remain vigilant to the subgroup of patients with persistently elevated HeRO Scores due to their profound risk of death, whereas consistently low HeRO Scores provide reassurance of low risk.

References

I use HeRO ... because the evidence matters

Clear Evidence of the Best Care:

- Heart rate characteristics monitoring and reduction in mortality or neurodevelopment impairment in extremely low birthweight infants with sepsis. Early Human Development
- Heart-rate-characteristic monitoring decreases NICU length of stay. JPed
- Predicting Extubation Outcomes - A Model Incorporating Heart Rate Characteristics Index. JPed
- New Technology is Life Saving Voice for Premature or Critically Ill Infants. Neo Today
- HeRO monitoring in the the NICU: sepsis detection and beyond. J Adv Neonatal Care

Contact us to learn more:
info@heroscore.com  800-394-1625
www.heroscore.com
Pregnancy requires an increased nutrient intake in order to support the growing fetus and maternal well-being. Maternal micronutrient deficiencies during pregnancy are associated with pregnancy complications, as well as adverse fetal growth and development. The vitamins and microelements required during pregnancy and lactation compared to the non-pregnant state are summarized in Table 1.

<table>
<thead>
<tr>
<th>Vitamin or Mineral</th>
<th>General Recommendations</th>
<th>Special Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Folic Acid</td>
<td>At least 0.4 daily for a minimum of 1 month before conception and the first 12 weeks of pregnancy</td>
<td>A higher daily dose of 5 mg recommended for women with increased risk of NTD</td>
</tr>
<tr>
<td>Iodine</td>
<td>All pregnant women should take 150 micrograms daily</td>
<td>Mandatory in areas of regional deficiency</td>
</tr>
<tr>
<td>Vitamin B12</td>
<td>Routine supplementation not recommended</td>
<td>Consider supplementation in pregnancy and lactation for women who are vegetarian or vegan</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>Routine screening and supplementation of vitamin D is not currently recommended</td>
<td>Offer vitamin D screening to women with limited exposure to sunlight</td>
</tr>
</tbody>
</table>

Vitamin D deficiency is associated with an increased risk of pregnancy complications, including pre-eclampsia, preterm birth, and low birth weight. Severe maternal vitamin D deficiency has been associated with biochemical evidence of disordered skeletal homeostasis, congenital rickets, and fractures in the newborn. Vitamin D deficiency is common among high-risk groups, vegetarians, women with limited sun exposure, and ethnic minorities, especially those with darker skin. In 2010, the food and nutrition board at the Institute of Medicine of the National Academies stated that an adequate intake of vitamin D during pregnancy and lactation is 600 international units daily. It is recommended that pregnant women increase their daily iron intake. Iron supplementation reduces the risk of maternal anemia and iron deficiency. There is evidence for an increase in preterm birth and low birth weight in settings where nutritional intake is poor. Hypocalcemia has been associated with pre-eclampsia. Therefore calcium supplementation is recommended as a preventative measure for pre-eclampsia, particularly in groups of women who avoid dairy products.

To address potential micronutrient deficiencies, many women take pregnancy multivitamins. Despite high-frequency use and widespread marketing and promotion, there is a lack of scientific evidence that routine supplementation with multivitamins is beneficial for pregnancy outcomes. In many cases, multivitamins may contain excessive amounts of vitamins and minerals. Such supplements may not be without harm. Supplementation with a combination of vitamins C and E from 12-18 weeks gestation was shown to increase the risk of fetal loss or perinatal death. Furthermore, vitamin A is known as a teratogen, a high intake during pregnancy is associated with an increased risk of congenital malformations. Therefore, some degree of caution regarding widespread routine supplementation practices is warranted. ACOG recommends vitamins that contain at least 600MG of folic acid, 200mg of DHA, 27 mg of iron, 1,000 mg of calcium, and 600 mg of vitamin D. Most brands (Olly, Nature Made Prenatal, Mama Bird, Smarty Pants, etc.) fulfill these criteria. The recommendations are to use them daily in all the trimesters of pregnancy. However, maternal-fetal demands and possible complications are trimester-dependent. Folic acid, for example, is much needed before conception and in the first trimester to decrease the risk of neural tube defects. Since the mid-1990’s health care organizations around the world have adopted policies designed to increase the dietary intake of folic acid before and during pregnancy to reduce the risk of having a
baby with a defect of the brain and/or spinal cord. Folic acid is the synthetic form of folate, a B-group vitamin naturally present in many foods, particularly leafy green vegetables. The MRC vitamin study group reported a 72% protective effect for folic acid in at-risk pregnancies. There is no proven need for folic acid supplementation after the closure of the neural tube. Calcium on the other hand is much needed in the second trimester with the rapid growth of the fetal skull and skeleton. Iron supplements are mostly needed in the second and third trimesters in anticipation of post-delivery blood loss. Many of the vitamins and supplements have side effects, e.g. constipation and nausea in case of iron supplementations.

An unsuccessful attempt to introduce a similar concept was undertaken by Perelel. (CA) They created trimester-specific packages e.g. the use of probiotics and Omega DHA for brain development, which at this time has no scientific basis. On the other hand, appropriate dosages of vitamin B3 and D in the first trimester are not included. Vitamin B3 is known to prevent miscarriages.

The Fetal Research Fund created a new type of prenatal vitamins based on the nutritional needs of individual patients and the trimester of pregnancy. Regarding vitamin D, Fetal Research Fund uses recommendation of the committee on Nutrition of the American Academy of Pediatrics which recommends that a daily intake higher than that recommended by the Food and Nutrition board may be needed to maintain maternal vitamin D sufficiency. Most experts agree that supplemental vitamin D is safe in dosages up to 4,000 international units per day during pregnancy or lactation.

References
10. Institute of Medicine of the National Academies (US) Dietary reference intakes for calcium and vitamin D. Washington, D.C: National Academy Press 2010
Measuring preterm infants’ cerebral oxygen levels in their first 96 hours of life via near-infrared spectroscopy (NIRS) can help identify patients at risk for death or severe neuroradiographic brain injury in early life, a recent study has demonstrated. Among 103 subjects, who were born at a mean gestational age of 26 weeks and weighed less than 1250 g at birth, cerebral oxygen saturation below 50% was significantly linked with the adverse outcomes measured in the study. The findings were published in December 2020 in the *Journal of Pediatrics*.

NIRS is a noninvasive method for measuring tissue oxygen saturation at the bedside. Preliminary research suggested that measuring cerebral oxygen levels with a NIRS sensor might provide clinically useful information about preemies’ risk of death or brain injury, but the idea has had only limited testing using sensor equipment designed for neonates.

The multicenter study, led by Stanford Children’s Health neonatologists Valerie Chock, MD, associate professor of pediatrics, and Krisa Van Meurs, MD, professor of pediatrics, enrolled infants during their first 24 hours of life and continuously measured their cerebral oxygen saturation via a NIRS sensor placed on each patient’s forehead, as well as their mean arterial blood pressure via an indwelling arterial line, until 96 hours of age. Twenty-one infants (20% of the study sample) were included in the primary outcome group because they died before hospital discharge (11 patients), or developed grade 3 or 4 intraventricular hemorrhage or periventricular leukomalacia in the first 10 days after birth (14 patients). Four patients who died also had severe intraventricular hemorrhage. During their first four days of life, infants with adverse outcomes spent significantly more time than other study subjects with cerebral oxygen saturation below 65%, 55% and 50%, the study found.

More research, including randomized trials, will be needed to determine what thresholds of oxygen saturation should trigger clinical actions, the researchers said. Future research could also ask whether cerebral oxygen saturation in early life has predictive value for long-term cognitive outcomes in preemies, and whether different outcomes are seen in babies who are small for gestational age in addition to being premature.

Still, the findings hold important clues to the utility of noninvasive monitoring of brain oxygen levels in the earliest-born and most vulnerable preemies, the researchers said. “Our study is the largest to date to link impaired regulation of cerebral blood flow in the first few days of life to mortality or early brain injury,” said Chock. “These findings underscore the need to maintain stable blood flow to the brain in very early and small preemies.”

**Noninvasive Technique to Track Early Preemies’ Cerebral Oxygen Levels Can Help Predict Neonatal Death, Brain Injury**

Erin Digitale

Measuring preterm infants’ cerebral oxygen levels in their first 96 hours of life via near-infrared spectroscopy (NIRS) can help identify patients at risk for death or severe neuroradiographic brain injury in early life, a recent study has demonstrated. Among 103 subjects, who were born at a mean gestational age of 26 weeks and weighed less than 1250 g at birth, cerebral oxygen saturation below 50% was significantly linked with the adverse outcomes measured in the study. The findings were published in December 2020 in the *Journal of Pediatrics*.

NIRS is a noninvasive method for measuring tissue oxygen saturation at the bedside. Preliminary research suggested that measuring cerebral oxygen levels with a NIRS sensor might provide clinically useful information about preemies’ risk of death or brain injury, but the idea has had only limited testing using sensor equipment designed for neonates.

The multicenter study, led by Stanford Children’s Health neonatologists Valerie Chock, MD, associate professor of pediatrics, and Krisa Van Meurs, MD, professor of pediatrics, enrolled infants during their first 24 hours of life and continuously measured their cerebral oxygen saturation via a NIRS sensor placed on each patient’s forehead, as well as their mean arterial blood pressure via an indwelling arterial line, until 96 hours of age. Twenty-one infants (20% of the study sample) were included in the primary outcome group because they died before hospital discharge (11 patients), or developed grade 3 or 4 intraventricular hemorrhage or periventricular leukomalacia in the first 10 days after birth (14 patients). Four patients who died also had severe intraventricular hemorrhage. During their first four days of life, infants with adverse outcomes spent significantly more time than other study subjects with cerebral oxygen saturation below 65%, 55% and 50%, the study found.

More research, including randomized trials, will be needed to determine what thresholds of oxygen saturation should trigger clinical actions, the researchers said. Future research could also ask whether cerebral oxygen saturation in early life has predictive value for long-term cognitive outcomes in preemies, and whether different outcomes are seen in babies who are small for gestational age in addition to being premature.

Still, the findings hold important clues to the utility of noninvasive monitoring of brain oxygen levels in the earliest-born and most vulnerable preemies, the researchers said. “Our study is the largest to date to link impaired regulation of cerebral blood flow in the first few days of life to mortality or early brain injury,” said Chock. “These findings underscore the need to maintain stable blood flow to the brain in very early and small preemies.”

**Noninvasive Technique to Track Early Preemies’ Cerebral Oxygen Levels Can Help Predict Neonatal Death, Brain Injury**

Erin Digitale

Measuring preterm infants’ cerebral oxygen levels in their first 96 hours of life via near-infrared spectroscopy (NIRS) can help identify patients at risk for death or severe neuroradiographic brain injury in early life, a recent study has demonstrated. Among 103 subjects, who were born at a mean gestational age of 26 weeks and weighed less than 1250 g at birth, cerebral oxygen saturation below 50% was significantly linked with the adverse outcomes measured in the study. The findings were published in December 2020 in the *Journal of Pediatrics*.

NIRS is a noninvasive method for measuring tissue oxygen saturation at the bedside. Preliminary research suggested that measuring cerebral oxygen levels with a NIRS sensor might provide clinically useful information about preemies’ risk of death or brain injury, but the idea has had only limited testing using sensor equipment designed for neonates.

The multicenter study, led by Stanford Children’s Health neonatologists Valerie Chock, MD, associate professor of pediatrics, and Krisa Van Meurs, MD, professor of pediatrics, enrolled infants during their first 24 hours of life and continuously measured their cerebral oxygen saturation via a NIRS sensor placed on each patient’s forehead, as well as their mean arterial blood pressure via an indwelling arterial line, until 96 hours of age. Twenty-one infants (20% of the study sample) were included in the primary outcome group because they died before hospital discharge (11 patients), or developed grade 3 or 4 intraventricular hemorrhage or periventricular leukomalacia in the first 10 days after birth (14 patients). Four patients who died also had severe intraventricular hemorrhage. During their first four days of life, infants with adverse outcomes spent significantly more time than other study subjects with cerebral oxygen saturation below 65%, 55% and 50%, the study found.

More research, including randomized trials, will be needed to determine what thresholds of oxygen saturation should trigger clinical actions, the researchers said. Future research could also ask whether cerebral oxygen saturation in early life has predictive value for long-term cognitive outcomes in preemies, and whether different outcomes are seen in babies who are small for gestational age in addition to being premature.

Still, the findings hold important clues to the utility of noninvasive monitoring of brain oxygen levels in the earliest-born and most vulnerable preemies, the researchers said. “Our study is the largest to date to link impaired regulation of cerebral blood flow in the first few days of life to mortality or early brain injury,” said Chock. “These findings underscore the need to maintain stable blood flow to the brain in very early and small preemies.”
Considerations for the Impact of a Tracheostomy: Respiration and Swallowing

Kristin A King, PhD, CCC-SLP and Gabriela Ortiz, BSRT, RCP

Effects of a Tracheostomy in Neonates
When a child is born prior to the full gestational period and is premature, the trajectory of their care is impacted by multiple factors. Often neonates considered at-risk fall into either a specific birth weight category or gestational age classification. Typically, infants fall into a birth weight category based on the classifications defined by the Center for Disease Control: extremely low birth weight (<1,000 g), very low birth weight (<1,500 g), low birth weight (<2,500 g), normal birth weight (<4,000 g), and high birth weight (>4,000 g) (Martin et al., 2011). An infant’s birth weight has been found to be a strong predictor of health outcomes, such as survival, risk of medical complications, and timing for the achievement of developmental milestones (Gill et al., 2013). Examples of complications associated with low to extremely low birth weight are hypothermia, hypoglycemia, perinatal asphyxia, respiratory distress, and several others. The lower the birth weight classification, the higher the risk of health complications.

Another classification process that is important to consider is the gestational age in combination with birth weight. For this classification, the system identifies if an infant is small for gestational age (below the 10th percentile), appropriate for gestational age (between the 10th and 90th percentiles), or large for gestational age (above the 90th percentile) (Gill et al., 2013). Particular health risks have been associated with the assigned classification.

When considering an infant that exhibits the respiratory complications that can arise with low birth weight, the interventions that become necessary also run risks of added complications. For example, upon intubation which causes alterations in airflow and pressures, the risks of decreased olfaction (loss of smell); diminished positive airway pressures; and changes in cough, cry, and phonation exist. With the diminished capacity to access these functions, secondary complications with decreased developmental milestones for feeding and swallowing, communication, and bonding may occur. With long-term respiratory support needs, having a tracheostomy may be considered; however, a tracheostomy is not without complications.

The need for an artificial airway is determined based on multiple factors, including life expectancy, birth weight, gestational age, comorbid conditions, congenital abnormalities, complications, and potential outcomes. At birth, the customary APGAR scoring system (1 to 10 scale) is commonly used. This assessment tool is a method for evaluating an infant’s health at the time of birth and summarizes the appearance (skin color), pulse, grimace (reflex to stimulation), activity (muscle tone), and respirations (APGAR) of the infant. If the infant presents with deficiencies and has an APGAR score of less than seven, therapeutic interventions by clinicians and other healthcare professionals will be conducted to increase the score. Assessment continues in short intervals to monitor progress. While the infant could present with a normal to midrange score at first, some also have demonstrated a rapid decline with presentation of such changes as shallow breathing, apnea, duskeness, and oxygen saturation between 70 and 80%. This process of evaluating based on the Apgar score assists with monitoring the need for immediate medical attention or the potential for long-term issues based on the scores at various time intervals.

Over time, the need for a tracheostomy tube has changed due to improvements in non-invasive ventilation options, but despite this advancement, tracheostomy placement has increased by 31% in the neonate population as reviewed from 2006-2012 (Wang et al., 2020). Placement often will depend on the philosophies of the facility and physicians as it relates to long-term ventilation needs and use of intubation. The occurrence of tracheostomy occurred most often in the extremely preterm neonates; however, the mortality rate was reported to be lower in those neonates receiving a tracheostomy as compared to those without a tracheostomy (18% vs 21%) (Wang et al., 2020). Overman et al. (2013) reported that infants with extremely low birth weights were more likely to have tracheostomies but found that even with high survival, developmental delays and comorbidities.
were prevalent in this patient population. Akangire et al. (2020) reported that the most common co-morbidity in this patient population is dysphagia, swallowing and feeding disorders.

Complications
Though a tracheostomy may be received shortly after birth, a retrospective study by Akangire et al., (2020) found that the mean age of tracheostomy was 4.5 months with median age of 3 months in their cohort, which was similar to other reports (Unal et al., 2015). Implications and the impact of a tracheotomy tube are multifactorial.

For some, a tracheostomy may not be permanent, but when in place the potential impacts are many. Having an open tracheostomy tube with or without mechanical ventilation may cause changes such as (Passy-Muir, Inc., 2021):
- Loss of sense of taste and smell.
- Reduced subglottic pressure.
- Decreased laryngeal and pharyngeal sensation, altering secretion management.
- Increased pooling of secretions.
- Reduced cough effort.

A tracheostomy tube is placed in the trachea to provide an access so that respiratory support occurs directly to the lower respiratory system; however, this placement of a tracheostomy tube bypasses the upper airway, eliminating or diminishing airflow out through the mouth and nose. This change in the direction of airflow is what has the potential impact on functions. These changes to the aerodigestive system also may impact development of feeding and swallowing skills, along with potential delay of communication, even infants communicate through the types of cries used to indicate hunger and pain. Having an infant lose the ability to cry and interact with the caregiver also may have a negative effect on bonding.

Infant Swallowing
When analyzing the respiratory side of swallowing in full-term, healthy infants, coordination is characterized by the cessation of breathing during swallowing process. The brief apneic period may occur in any of the following stages of respiration: mid-inspiration, mid-expiration, and between inspiration and expiration or expiration and inspiration. Having a tracheostomy tube, and especially with mechanical ventilation, may disrupt this cycle.

The act of swallowing is a complex and multi-faceted act that begins developing in utero, which requires the use of structures and functions that also are utilized during respiration, swallowing, and phonation (Pullens & Streppel, 2021). Infants start to experience swallowing around 11 to 12 weeks of the gestational period and suckling at approximately the 24th week of gestation. Lau (2015) reports that a child may breathe at a rate of 40-60 breaths per minute (bpm) or 1.5-1 breaths per second for the typically developing infant. If an infant exhibits an immature swallow, and immature swallows may last from 0.35 to 0.75 seconds, then this may cause breathing to be compromised. These impacts are regardless of the presence of a tracheostomy tube. The difficulties may arise with the attempts to coordinate respiration and swallowing in the infant, especially with either delayed or disordered swallow function.

Now, consider the negative impact of a tracheostomy tube on the trachea, compounding the difficulty if the infant already has a compromised system. Typically, the normal movement of the larynx helps protect the airway and open the esophagus during swallowing. However, when a tracheostomy tube is placed, the possibility of laryngeal tethering increases, and hyolaryngeal excursion may slow due to interruption and sometimes stoppage of the upward and forward movement of the larynx during swallowing. Birutis et al. (n.d.) reported that when studying infants with tracheostomy tubes, they found that both the presence of a tracheostomy tube and the age of the infant were factors in the occurrence of aspiration; however, duration time with a tracheostomy tube was not a factor. They also found that of those children who aspirated, 93.3% of them did so silently; however, of note, they found that the younger the child, the lower the incidence of aspiration.

Another factor is the alteration of subglottal pressure during swallowing, which may affect how the vocal folds close. Normally, the air pressure builds underneath the vocal folds to establish subglottic pressure, with this pressure occurring during speech, sound production, swallow, cough, and throat clear. The pressure that builds during swallowing assists with the hyolaryngeal excursion and is exhaled at the end of a swallow. This process assists with sensation, bolus clearance, and airway protection. Any food or liquid that may have entered the airway may be cleared by the force from the exhaled airflow. Unfortunately, the presence of an open tracheostomy tube prevents the creation of subglottal pressure during a swallow. For that matter, all types of pressure in the aerodigestive tract are compromised when an open tracheostomy tube is placed. Pressure to assist with bolus transition through the pharyngeal area diminishes and may lead to increased residue or decreased cricopharyngeal opening during the swallow. Another aspect
of pressure that is negatively impacted is the ability to build backpressure as a part of the physiologic positive end-expiratory pressure (PEEP), which is needed to keep the alveoli open for appropriate gas exchange. Having diminished PEEP strains the mechanisms for ventilation and oxygenation.

Separate from potential impacts on movement and pressure during the swallow is that without airflow to the upper airway, loss or decrease in the sensitivity in the upper airway may be affected. This decrease in stimulation compromises sensation, which will not allow sufficient stimulation for effective swallow or cough; thereby, seriously compromising airway protective reflexes which would normally react to stop food and liquid from going into the airway and lungs.

While the act of feeding and swallowing may directly impact the ability to coordinate respiration and swallowing, another effect is the influence on respiratory rate. During feeding, the respiratory rate may decrease, which in turn impacts minute ventilation. The effect on the minute ventilation may prolong the expiratory phase and shorten the inspiratory phase. Changes in the phases of respiration may affect both the safety and effectiveness of the swallow. It is important to acknowledge that impaired breathing may negatively affect swallowing.

Restoring airflow and pressures

Studies have shown that placement of a no-leak speaking valve helps restore the pressurized systems; therefore, wearing a speaking valve may assist with restoring subglottal pressure (Gross et al., 2003; Gross et al., 2006). Research and studies also have indicated that the application of the no-leak Valves not only restores pressure but also restores voicing, improves laryngeal and pharyngeal sensation, improves swallow and cough, and in some patients may improve swallow function (Gross et al., 2003; Brooks et al., 2019; O’Connor et al., 2018).

The Passy-Muir® Valve (PMV) allows the patient to breathe in through the tracheostomy tube but is only open during active inhalation, redirecting airflow up to the upper airway through the vocal folds and out through the mouth and nose during exhalation. This redirection of airflow and re-engagement of the valving mechanisms in the subglottic region helps restore the body’s physiologic pressures. Brooks et al. (2019) reported that use of the no-leak PMV is being underutilized with infants and children who are medically fragile, whether on mechanical ventilation or tracheostomy collar. The study provides evidence as to the factors that predict successful use of the PMV. The authors report that vocalizing, transtracheal pressures, age, and weight are all associated with successful use. When the patient is on a ventilator, the only related factor specific to mechanical ventilation that predicted successful use of the PMV inline was ventilator rate; PEEP pressure support, and FiO₂ were not correlated or predictors of the ability to use the Valve. With the higher risk that has been identified in pre-term infants for respiration, coordination and swallowing, and aspiration, providing restored functions and pressures may assist with improved status. Research in adults has shown that early use of a no-leak speaking Valve leads to earlier weaning and decannulation (O’Connor et al., 2018; Rodrigues et al., 2015). More research is needed in this area for pediatrics.

Conclusion

As a result of physiologic changes following tracheostomy, limitations may be imposed on the coordination of breathing and sucking for nutritive and non-nutritive purposes. The term obligate nose breathing is used to define the normal breathing of infants who rely on the autonomic system and the ability to synchronize activities of sucking, swallowing, breathing and esophageal function in proper sequence. Without the proper coordination of respiratory and subglottic function, safe oral feeding may become an issue and drastically impact the quality of life (QOL) of a child. It is essential that swallowing be a consideration for monitoring, evaluation, and intervention when an infant has to have a tracheostomy tube.

References

- Overman, A. E., Liu, M., Kurachek, S. C., Shreve, M.


A Nutritional Approach to Feeding a Targeted Bacterial Strain in the NICU

Michael J Fitzgerald, MD

Probiotic use in the NICU has been considered as a promising tool for the prevention of necrotizing enterocolitis (NEC) with a focus on the very low birth weight (VLBW) population of infants <32 weeks or <1500 grams, and the data appear to show a lower risk of NEC in preterm infants fed a probiotic. However, from a pharmaceutical perspective, the evidence and precision on which strains, or how much of each strain, to use for NEC prevention is inconclusive, primarily due to a lack of understanding or focus on the mechanism of action. As a result, expert groups have conflicting viewpoints.

This dichotomy is clear from two recently published articles regarding the use of probiotics in the NICU. The first was a meta-analysis of 56 RCTs and 30 observational studies (including over 80,000 patients total) on the use of probiotics to prevent NEC, published in the Journal of the American Medical Association (JAMA) Pediatrics. After evaluating the results, Razak et al. suggested that the evidence supports the routine use of probiotics for preterm infants. The authors further referenced support for this recommendation by citing the Canadian Pediatric Society guidelines, the American Gastroenterology Association, and the European Society for Paediatric Gastroenterology Hepatology and Nutrition.

A contrary viewpoint was written by the American Academy of Pediatrics (AAP) Committee on Fetus and Newborn. The Committee took the position that, due to the lack of FDA-regulated pharmaceutical products and the heterogeneity of the clinical data between different probiotics, the current evidence does not support routine administration of probiotics to preterm infants.

Given that preterm infants are a particularly vulnerable population, the cautionary tone from the AAP committee regarding safety is well warranted. However, the specific and narrow pharmaceutical perspective on probiotic use to treat NEC does not represent the whole story of patient care in the NICU. Proposed here is a new lens through which to view NICU probiotic use, focusing on a nutritional rather than a pharmaceutical intervention to provide comprehensive management of the preterm gut microbiome, leading to overall improved health outcomes in preterm infants, including NEC.

Differentiating between a pharmaceutical vs nutritional approach when utilizing probiotics as standard of care:

It is well established in the literature that preterm infants acquire high levels of nosocomial pathogenic bacteria in their gut microbiome. This may disrupt evolutionarily appropriate gut assembly, resulting in microbiome instability and a loss of function. This imbalance of pathogenic and beneficial bacteria causes enteric inflammation and puts preterm infants at risk for a number of adverse outcomes. Managing this microbial imbalance in the preterm gut should be a clear patient care goal in the NICU. Said another way, if a *Bifidobacterium* dominant microbiome in a breast-fed infant is natural and developmentally appropriate in early infancy, it stands to reason that achieving this should be a milestone in the care of premature infants.

Research published by Nguyen et al. in 2021 shows that modulation of the gut microbiome is achievable in preterm infants without the use of antibiotics through the nutritional approach of feeding a targeted bacterial strain, activated *B. infantis* EVC001 (EVC001) in addition to human milk. Contrary to most probiotic strains on the market, which have been selected based on availability and production characteristics rather than function, the EVC001 bacterial strain was determined as an infant gut symbiont that works synergistically with human milk to provide benefits to the infant, including colonization resistance to opportunistic pathogens.

EVC001 was selected specifically for its growth characteristics on human milk oligosaccharides (HMO), the third most abundant class of nutrients in human milk, as evidenced in the EVC001 genome. Compared to other *B. infantis* strains, EVC001 has a functional H5 gene cluster important in the ability to use HMO, which highlights the importance of selecting specific strains for their ability to modulate the microbiome in an age- and diet-appropriate manner. The EVC001 strain is commercially available in the product Evivo with MCT Oil which is designated as a Food for Special Dietary Use (FSDU) specifically to meet dietary needs that exist due to age of infancy and lactation. Evivo with MCT Oil is regulated as a food under the FDA Food Safety Modernization Act, not under dietary supplement regulations.

Feeding EVC001 along with human milk is a nutritional solution with an established mechanism of action, unique in providing a comprehensive approach to improving newborn gut health. This nutritional approach provides a broad spectrum of biological benefits to the infant through the ability to completely break down HMO. As a result of these biological changes in the gut, observational studies...
from NICUs using EVC001 as standard of care have reported significant improvements in intrinsic factors related to the onset of NEC, including reduction in enteric inflammation and reduced abundance of Enterobacteriaceae, such as E. coli and Klebsiella oxytoca. In addition to NEC-related benefits, clear indicators of improved gut health, such as significant reduction in diaper dermatitis and antibiotic usage, have been seen in preterm infants receiving EVC001.

Given the above clinical outcomes and the known mechanisms of action, numerous prominent healthcare institutions have successfully introduced the routine use of B. infantis EVC001 in their NICUs, including use in extremely low birth weight (ELBW) infants.

In conclusion, comprehensive management of the preterm infant gut through nutritional intervention aimed at modulating the microbiome can yield health benefits to the infant, including the reduction or elimination of known causative factors related to NEC. As demonstrated in clinical studies using EVC001, this is possible due to the unique capacity of the EVC001 strain to utilize specific components of human milk (i.e., HMOs), colonize the infant gut, displace hospital acquired microorganisms, and produce specific metabolites that lower enteric inflammation and modulate the immune system.

Addressing the safety of activated B. infantis EVC001 as a high-quality nutritional product:
Routine use of high-quality food-grade nutritional products is commonly practiced in NICUs across the United States. The targeted EVC001 bacterial strain in Evivo with MCT Oil was selected for use in the NICU at Edward-Elmhurst because of the manufacturer’s commitment to high quality standards with rigorous testing throughout the end-to-end product life cycle and transparent labeling with 8 billion CFU of the designated EVC001 strain guaranteed through the ‘best if used by’ date.

Selecting a NICU-appropriate form was also important when adopting Evivo as part of the feeding protocol at Edward-Elmhurst. Contrary to other products, Evivo with MCT Oil is designed with the neonate in mind, manufactured in a single-use, ready-to-feed liquid which facilitates adherence to the Infant and Pediatric Feeding 3rd Edition recommendation. Finally, but most importantly, B. infantis is an infant gut symbiont and the EVC001 strain is a non-pathogenic species, lacking virulence factors and has been fed under the care and direction of health professionals as a microbiome management product many thousands of times to preterm infants, including ELBW infants, as a nutritional product.

Pointing to recent and future research of EVC001 in preterm infants:
A series of strong and consistent data on the unique benefits of activated B. infantis EVC001 have been presented in recent published clinical trials and recently presented at neonatology conferences such as Cool Topics in Neonatology, Hot Topics in Neonatology and the NEC society. Furthermore, a clinical trial was recently completed at Winnie Palmer Hospital in Orlando FL which systematically assessed safety and tolerability of the product among preterm infants <1500 grams or gestational age at birth <33 weeks. This study adds to a growing body of data that demonstrates how feeding EVC001 to preterm infants in the NICU provides care givers with a new tool to address comprehensive management of the infant gut microbiome, leading to improved global gut health and overall healthier infants. Additionally, the beneficial impact of actively managing the preterm infant gut microbiome was obvious from a recent study at Oregon Health and Science University which showed significant reductions in NEC and NEC-related mortality among VLBW and especially ELBW infants fed Evivo with MCT Oil.

Concluding remarks
While the AAP Committee Report wisely raises awareness over the need for high quality probiotics for the preterm population, their view on probiotics solely as a drug for the prevention of NEC is very narrow. A drug implies a certain amount of accepted risk to solve the indication; however, if missing symbionts and overabundance of hospital acquired bacteria are a root cause and key to the overall health of the preterm infant, a more global approach needs to be considered.

Over the past few years, it has become clear that the gut microbiome is an important “microbiological organ” that, if managed properly, has been implicated in many beneficial aspects of neonatal health, including the reduction of opportunistic pathogens, antimicrobial resistance, enteric inflammation, diaper dermatitis and feeding intolerance, all issues that greatly affect preterm outcomes in the NICU. Given that the AAP’s Committee on Fetus and Newborn may not issue another report for several years and gut microbiome science and clinical usage is rapidly developing, clinicians are encouraged to follow new research carefully to make the best evidence-based, informed decisions for their patients. Finally, we should consider nutritional-based approaches to comprehensively manage the infant gut microbiome for the improvement of all health outcomes, including NEC, in addition to the pharmaceutical approach as suggested by the recent AAP Committee Report. If indeed, the effective nutritional management of the preterm infant gut sets up conditions that do not allow the overgrowth of pathogenic bacteria that contribute to NEC, there may no longer be a need for a pharmaceutical intervention to treat it.

References
6 Poindexter, B. and COMMITTEE ON FETUS AND NEWBORN. Use of Probiotics in Preterm Infants. Pediatrics 147, e2021051485 (2021)
7 Grier, A. et al. Impact of prematurity and nutrition on the...


17 Tobias, J. *et al.* Feeding Activated *Bifidobacterium infantis* EVC001 to Very Low Birth Weight Infants is Associated with Significant Reduction in Rates of Necrotizing Enterocolitis. *medRxiv* doi:10.1101/2021.06.29.21259737 (2021)

What Clinicians Need to Know About Human Milk Banking, Including Regulations

In this feature, Neonatal Intensive Care interviews clinicians and healthcare providers about the actual application of specific products and therapies. This interview is with Olivia Mayer RD, CSP, IBCLC, Clinical Dietitian, NICU specialist.

Demand for donor human milk is booming with new purveyors selling everything from supplements to beauty products made from it. What do clinicians need to know about the latest developments in human milk banking?

Clinicians should be aware that this massive growth in the amount of donor human milk being collected from various sources for an array of purposes is both good and bad news. The good news is that awareness of the benefits of donor human milk to premature infants, for whom it can be lifesaving, has increased. The bad news is that, lacking comprehensive regulations or enforcement of existing regulations, the donor human milk industry is, at present, not without avoidable risk.

At the rigorous end of the spectrum are organizations such as the nonprofit Human Milk Banking Association of North America (HMBANA), which has established protocols for human milk collection, pasteurization, and distribution, and for-profit companies (eg, Prolacta Bioscience was the first of its kind) that develop products exclusively for premature and critically ill infants and maintain rigorous protocols for screening and testing donors as well as for storing, processing, and testing donor human milk. At the other extreme is the open market. There are a growing number of internet sites where mothers barter, sell, or donate their breastmilk without any formal screening, testing, or processing. In between lie new purveyors of human milk, with varying methods for ensuring the safety and quality of the donor human milk they collect and the safe and ethical treatment of the donors themselves. Before administering or recommending human milk to patients, clinicians should be aware of the source and safety precautions involved.

How are donor human milk products regulated? Are there standardized quality and safety protocols?

The American Academy of Pediatrics states that “[f]ederal or state guidelines are needed regarding the preparation, handling, and transfer of human milk as well as the operation of donor human milk banks and would be best accomplished via formal regulation by the US Food and Drug Administration [FDA] with oversight by the Centers for Disease Control and Prevention.”

Unfortunately, the FDA does not regulate human milk the way it does blood, semen, or other biologics. While regulations vary from state to state, many milk banks selling donor human milk are required only to register with the FDA as a food manufacturer. Some may additionally follow voluntary guidelines, such as those published by HMBANA, but these are not monitored or enforced by any outside regulatory agency. There are internet-based or in-person community milk sharing companies or groups that may function entirely outside the confines of current FDA regulations.

There is a dire need for increased oversight of human milk banks by the federal government in the United States. Until this is addressed, buyer beware!

What safety concerns should hospitals and clinicians be apprised of?

This boom in the donor human milk industry poses a major safety concern for premature and critically ill infants who can benefit the most from donor human milk. Given their fragile state, these infants simply cannot tolerate exposure to even minute levels of foreign proteins, adulterants, pathogens, toxins, or drug metabolites that could be present in improperly screened, tested, or processed human milk.

To keep costs low, some new purveyors of donor human milk are employing the practice of using food processing methods, rather than treating human milk as the biologic entity that it is. But the risks associated with infected or adulterated donor human milk are far greater than those posed by food. We have only to look to the inadequate screening of blood and other human tissue in the 1980s and ’90s, during which time thousands of people were needlessly infected with HIV or hepatitis, to be reminded of the potential risks.

How can clinicians ensure that the donor human milk they are receiving is safe for use in premature and critically ill infants?

To ensure their products are safe and beneficial, it is important that manufacturers of human milk products can answer the following questions:

1. How were donors screened? Donors should undergo a thorough health screening and blood testing for infectious diseases as well as the use of drugs or medications that can pass into breastmilk, such as nicotine and THC. They should also provide updated information about any recent travel, particularly to areas where diseases of concern, such as Zika, may be endemic. Donors and their infants should also be screened by a

If you would like to participate in this feature, as a company or healthcare provider, please contact Steve Goldstein at s.gold4@verizon.net
physician to ensure that the act of donating milk does not risk harming either of them in any way.

2. How was the milk stored and processed? To ensure that donor human milk is safe and free of any pathogenic microorganisms or toxins, proper storage and processing is essential. All donor milk should be processed using time and temperature profiles defined by the FDA in its Pasteurized Milk Ordinance (PMO) to ensure destruction of pathogenic bacteria. Processing methods should effectively destroy pathogens while also maintaining the maximum bioactivity of the milk. Notably, ultra-high-temperature (UHT) sterilization and retort sterilization diminish the bioactivity of human milk. In contrast, while vat and Holder pasteurization also destroy pathogenic microorganisms, studies have shown they better retain milk bioactivity. This includes maintenance of secretory immunoglobulin A (sIgA) and lysozyme activity, as well as concentrations of the immune modulating proteins IgA, IgM, IgG, lactoferrin, lysozyme, α-lactalbumin, α-antitrypsin, casein; human milk oligosaccharides (HMOs); and HMOs containing fucosic, sialic acid, and nonfucosylated neutral sugars. Finally, donor milk should not be homogenized, as this can disrupt milk fat globules (MFGs) and milk fat globule membranes (MFGMs), which have been shown in their intact state to improve immune defenses, reduce inflammation, reduce the risk of infections, improve gut function, and support infant development.

3. How was the milk tested? Even with the most scrupulous donor screening and human milk processing, there is the remote possibility that pathogens, toxins, drug metabolites, or adulterants that could harm fragile infants might find their way into donor milk. Even with regular blood tests, there remains the possibility that donors could contract a pathogen or seroconvert from negative to positive between blood screenings. To address this risk, the responsibility for surveillance and monitoring would then fall to the processing company to continually screen the donated milk. Prolacta Bioscience has recently enhanced its nucleic acid amplification test (NAAT). This NAAT directly tests donated milk for the presence of pathogens that include Zika (ZIKV), syphilis, HIV-1 and 2, human T-lymphotropic virus (HTLV) type I and II, hepatitis B and C, and tuberculosis. This has now been expanded to include SARS-CoV-2, the virus that causes COVID-19. This ability is an example of continued surveillance and monitoring of the milk donations received.

4. What is in the milk? Purveyors of human milk-based nutritional products should have processes in place to ensure that their products provide the same level of nutrition every time. Standardized labeling with nutrient levels addresses this need and gives clinicians confidence when prescribing human milk products to vulnerable populations.

5. What do the clinical data say? When using donor human milk as medicine, there must be complete transparency regarding how donors were screened as well as how the milk was collected, stored, processed, and tested. Final products should be supported by evidence demonstrating safety and efficacy. There is no defensible reason to use human milk-based products that lack such clinical evidence efficacy in fragile neonates. To do so is tantamount to conducting an uncontrolled trial without informed consent in an extremely vulnerable population.

Harnessing the therapeutic power of human milk has the potential to meaningfully improve the sometimes-discouraging outcomes of fragile neonates. As with many paradigm shifts, the donor human milk market has advanced ahead of the regulation. While the potential for benefit remains extremely encouraging, proper regulation will ensure that this benefit is not offset by avoidable risk. In the meantime, it is the responsibility of every clinician using human milk products to remain scrupulous about the quality, safety, and efficacy of the products they choose to use.

References
For your patients with a rare and devastating genetic disorder¹,²

With MoCD Type A, waiting is not an option¹,²

Introducing NULIBRY, an FDA-approved therapy for patients with MoCD Type A to reduce the risk of mortality.¹ MoCD Type A, the most common form of MoCD, is a rare and devastating inborn error of metabolism (IEM) that presents shortly after birth, progresses rapidly, causes irreparable damage, and often leads to an early death (median survival age is 4 years).¹,²

NULIBRY is a cyclic pyranopterin monophosphate (cPMP), replacing a critical component the body needs to make molybdenum cofactor (MoCo). NULIBRY is administered as a daily intravenous (IV) infusion after reconstitution. Dosing is individualized based on the patient’s actual weight. NULIBRY is a cold chain product and comes as a powder or cake in a single-dose, clear glass vial.¹

As soon as MoCD Type A is suspected, consider NULIBRY.¹*

INDICATION
NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS
Potential for Photosensitivity
NULIBRY can make the patient oversensitive to sunlight. NULIBRY-treated patients or their caregivers are advised to avoid or minimize patient exposure to sunlight and artificial UV light and adopt precautionary measures when exposed to the sun, including wearing protective clothing and sunglasses, and use broad-spectrum sunscreen with high SPF in patients 6 months of age and older. If photosensitivity occurs, caregivers/patients are advised to seek medical attention immediately and consider a dermatological evaluation.

ADVERSE REACTIONS
The most common adverse reactions in NULIBRY-treated patients were infusion catheter-related complications (89%), pyrexia (fever) (78%), viral infection (56%), pneumonia (44%), otitis media (ear infection) (44%), vomiting (44%), and cough/sneezing (44%). Adverse reactions for rcPMP-treated patients were similar to the NULIBRY-treated patients.

PATIENT COUNSELING INFORMATION
Please read the FDA-approved NULIBRY Prescribing Information and Instructions for Use and follow the instructions on how to prepare and administer NULIBRY.

NULIBRY has a potential for photosensitivity; see Warnings and Precautions. Seek medical attention immediately if the patient develops a rash or if they notice symptoms of photosensitivity reactions (redness, burning sensation of the skin, blisters).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also call BridgeBio at 1-844-550-BBIO (2246).
In children with MoCD Type A, NULIBRY (or recombinant cPMP [rcPMP]) was shown to¹:

- Improve overall survival vs untreated, genotype-matched natural history controls¹
- Reduce and maintain reductions of toxic S-sulfocysteine (SSC)¹

*Discontinue NULIBRY if the MoCD Type A diagnosis is not confirmed by genetic testing.

Visit NULIBRY.com to learn how you can give patients with MoCD Type A a fighting chance¹


Please see accompanying Brief Summary.

NULIBRY.com
NULIBRY is a trademark of Origin Biosciences, Inc. Origin Biosciences is a member of the BridgeBio family. ©2021 Origin Biosciences, Inc. All rights reserved. US-cPMP-2000082 03/21
NULIBRY™ (fosdenopterin) for injection

BRIEF SUMMARY: For full prescribing information, see package insert.

1 INDICATIONS AND USAGE

NULIBRY is cyclic pyranopterin monophosphate (cPMP) indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.

2 DOSAGE AND ADMINISTRATION

2.1 Patient Selection

Start NULIBRY if the patient has a diagnosis or presumptive diagnosis of MoCD Type A.

In patients with presumptive diagnosis of MoCD Type A, confirm the diagnosis of MoCD Type A immediately after initiation of NULIBRY treatment. In such patients, discontinue NULIBRY if the MoCD Type A diagnosis is not confirmed by genetic testing.

2.2 Important Administration Information

• NULIBRY is intended for administration by a healthcare provider. If deemed appropriate by a healthcare provider, NULIBRY may be administered at home by the patient's caregiver. If NULIBRY can be administered by a caregiver/patient, advise them to read the detailed instructions on the preparation, administration, storage, and disposal of NULIBRY for caregivers [see Instructions for Use].

• NULIBRY is for intravenous infusion only. Administer with non-DEHP tubing with a 0.2 micron filter. Do not mix NULIBRY with other drugs (note NULIBRY is reconstituted with Sterile Water for Injection, USP). Do not administer as an infusion with other drugs.

• NULIBRY is given through an infusion pump at a rate of 1.5 mL per minute.

• Dose volumes below 2 mL may require syringe administration through slow intravenous push.

• Administration of NULIBRY must be completed within 4 hours of reconstitution [see Dosage and Administration (2.5)].

2.3 Recommended Dosage and Administration

Recommended Dosage and Administration in Patients Less Than One Year of Age (by gestational age)

The recommended dosage regimen of NULIBRY in patients less than one year of age (by gestational age) is based on actual body weight as shown in Table 1.

Table 1 Recommended Initial Dosage and Titration Schedule of NULIBRY for Patients Less Than One Year of Age by Gestational Age

<table>
<thead>
<tr>
<th>Titration Schedule</th>
<th>Preterm Neonates (Gestational Age Less than 37 Weeks)</th>
<th>Term Neonates (Gestational Age 37 Weeks and Above)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial Dosage</td>
<td>0.4 mg/kg once daily</td>
<td>0.55 mg/kg once daily</td>
</tr>
<tr>
<td>Dosage at Month 1</td>
<td>0.7 mg/kg once daily</td>
<td>0.75 mg/kg once daily</td>
</tr>
<tr>
<td>Dosage at Month 3</td>
<td>0.9 mg/kg once daily</td>
<td>0.9 mg/kg once daily</td>
</tr>
</tbody>
</table>

Recommended Dosage and Administration in Patients One Year of Age or Older

For patients one year of age or older, the recommended dosage of NULIBRY is 0.9 mg/kg (based on actual body weight) administered as an intravenous infusion once daily.

Recommendations for a Missed Dose

If a NULIBRY dose is missed, administer the missed dose as soon as possible. Administer the next scheduled dose at least 6 hours after the administration of the missed dose.

2.4 Preparation and Administration Instructions

NULIBRY must be reconstituted prior to use. Use aseptic technique during preparation and follow these instructions:

1. Determine the total dose, number of vials needed, and total reconstituted dose volume based on the patient's weight and prescribed dose.

2. Remove the required number of vials from the freezer to allow them to reach room temperature (by hand warming for 3 to 5 minutes or exposing to ambient air for approximately 30 minutes).

3. Reconstitute each required NULIBRY vial with 5 mL of Sterile Water for Injection, USP. Gently swirl the vial continuously until the powder is completely dissolved. Do not shake. After reconstitution, the final concentration of NULIBRY reconstituted solution is 9.5 mg/5 mL (1.9 mg/mL).

4. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Reconstituted NULIBRY is a clear and colorless to pale yellow solution. Do not use if there are particles present or if the solution is discolored.

5. Administer the total reconstituted dose.

2.5 Storage of Reconstituted Solution

Reconstituted NULIBRY may be stored at room temperature [15°C to 25°C (59°F to 77°F)] or refrigerated [2°C to 8°C (36°F to 46°F)] for up to 4 hours including infusion time. If reconstituted NULIBRY is refrigerated, allow it to come to room temperature (by hand warming for 3 to 5 minutes or exposing to ambient air for approximately 30 minutes) before administration. Do not heat. Do not re-freeze NULIBRY after reconstitution. Do not shake.

Discard all unused reconstituted NULIBRY solution 4 hours after reconstitution.

3 DOSAGE FORMS AND STRENGTHS

For injection: 9.5 mg of fosdenopterin, as a white to pale yellow lyophilized powder or cake in a single-dose vial for reconstitution.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Photosensitivity

Animal studies have identified that NULIBRY has phototoxic potential [see Nonclinical Toxicology (13.2)].

Advise NULIBRY-treated patients or their caregivers to avoid or minimize patient exposure to direct sunlight and artificial UV light exposure (i.e., UVA or UVB phototherapy) and adopt precautionary measures (e.g., have the patient wear protective clothing and hats, use broad spectrum sunscreen with high sun protection factor (SPF) in patients 6 months of age and older, and wear sunglasses when exposed to the sun). If photosensitivity occurs, advise caregivers/patients to seek medical attention immediately and consider a dermatological evaluation.
6 ADVERSE REACTIONS

6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Overview of Safety Evaluation
The safety of NULIBRY was assessed in 37 pediatric patients and healthy adults who received at least one intravenous infusion of NULIBRY or an E. coli derived non-salt, anhydrous form of cPMP (recombinant cPMP or rcPMP, which has the same active moiety and therefore the same biologic activity as NULIBRY). Of these 37 patients/healthy adults, 13 were pediatric patients with MoCD Type A in Studies 1, 2, and 3 [see Clinical Studies (14)]; 6 were pediatric patients with presumptive MoCD Type A but who were later confirmed to not have MoCD Type A, and 18 were healthy adults (without MoCD Type A) in a Phase 1 study.

Adverse Reactions
Assessment of adverse reactions for NULIBRY is based on data from two open-label, single-arm studies. Study 1 (n=8) and Study 2 (n=1), in patients with a confirmed diagnosis of MoCD Type A (8 of the 9 patients were previously treated with rcPMP). In these studies, patients received a daily intravenous infusion of NULIBRY. The median exposure to NULIBRY was 4.3 years and ranged from 8 days to 5.6 years [see Clinical Studies (14)]. In these studies, 44% of patients were males and 56% were females, 67% were White and 33% were Asian. The mean age was 14 days and ranged from 1 day to 69 days at time of first infusion.

Table 2 presents the most common adverse reactions that occurred in NULIBRY-treated patients in Studies 1 and 2.

Table 2 Common Adverse Reactions Reported in Two or More NULIBRY-Treated Patients with MoCD Type A (Studies 1 and 2)

<table>
<thead>
<tr>
<th>Adverse Reactions</th>
<th>NULIBRY-Treated Patients (N=9) n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catheter-related complications¹</td>
<td>8 (89%)</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>7 (78%)</td>
</tr>
<tr>
<td>Viral infection</td>
<td>5 (56%)</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>4 (44%)</td>
</tr>
<tr>
<td>Otitis Media</td>
<td>4 (44%)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>4 (44%)</td>
</tr>
<tr>
<td>Cough/Sneezing</td>
<td>4 (44%)</td>
</tr>
<tr>
<td>Upper respiratory infection</td>
<td>3 (33%)</td>
</tr>
<tr>
<td>Gastroenteritis</td>
<td>3 (33%)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3 (33%)</td>
</tr>
<tr>
<td>Bacteremia</td>
<td>3 (33%)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>2 (22%)</td>
</tr>
<tr>
<td>Influenza</td>
<td>2 (22%)</td>
</tr>
<tr>
<td>Lower respiratory tract infection</td>
<td>2 (22%)</td>
</tr>
</tbody>
</table>

Abbreviations: MoCD = molybdenum cofactor deficiency
¹ Catheter-related complications included complications associated with device, catheter site abscess, catheter site discharge, catheter site extravasation, catheter site pain, catheter site infection, catheter site inflammation, device dislocation, device leakage, device occlusion, and vascular device infection.

Safety data are also available from 10 patients with MoCD Type A who received rcPMP in Study 3 (an observational study) [see Clinical Studies (14)]. The median time on rcPMP treatment was 1.5 years and ranged from 6 days to 4.4 years. In Study 3, the patient population was evenly distributed between males and females with a mean age of 18 days (range 1, 69) at time of first infusion, 70% were white, and 30% were Asian.

In Study 3, one patient died of necrotizing enterocolitis. Adverse reactions for the rcPMP-treated patients were similar to the NULIBRY-treated patients, except for the following additional adverse reactions that were reported in more than one patient: sepsis, oral candidiasis, varicella, fungal skin infection, and eczema.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy
Risk Summary
There are no available data on NULIBRY use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction toxicology studies have not been conducted with NULIBRY.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively.

8.2 Lactation
Risk Summary
There are no human or animal data available to assess the presence of NULIBRY or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production for the mother.

The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NULIBRY and any potential adverse effects on the breastfed infant from NULIBRY or from the underlying maternal condition.
8.4 Pediatric Use
Safety and effectiveness of NULIBRY for the treatment of MoCD Type A have been established in pediatric patients starting from birth. Use of NULIBRY for this indication is supported by evidence from two open-label studies (Studies 1 and 2) and one observational study (Study 3), in which 13 pediatric patients aged birth to 6 years of age were treated with NULIBRY or rcPMP. Pediatric use information is discussed throughout the labeling.

Animal studies have identified that NULIBRY has phototoxic potential. Advise NULIBRY-treated patients or their caregivers to avoid patient exposure to direct sunlight and artificial UV light exposure (i.e., UVA or UVB phototherapy) and adopt precautionary measures [see Warnings and Precautions (5.1) and Nonclinical Toxicology (13.2)].

8.5 Geriatric Use
MoCD Type A is largely a disease of pediatric patients. Clinical studies of NULIBRY did not include patients 65 years of age and older.

DRUG INTERACTION STUDIES
In Vitro Studies
Fosdenopterin does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4/5. Fosdenopterin does not induce CYP1A2, CYP2B6, or CYP3A4.

Fosdenopterin is a weak inhibitor of MATE2-K and OAT1, but does not exhibit P-gp, BCRP, OATP1B1, OATP1B3, OCT2, OAT3, and MATE1.

Fosdenopterin is a weak substrate for MATE1, but is not a substrate of P-gp, BCRP, OATP1B1, OATP1B3, OCT2, OAT1, OAT3, or MATE2-K.

13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenicity studies have not been conducted with fosdenopterin.

Fosdenopterin was not genotoxic in a standard battery of in vitro (bacterial reverse mutation and human lymphocyte chromosomal aberration) and in vivo (rodent bone marrow micronucleus) assays.

Fertility studies have not been conducted with fosdenopterin.

13.2 Animal Toxicology and/or Pharmacology
Fosdenopterin has demonstrated phototoxic potential in an animal study at doses equal to and greater than 4.5 times the maximum recommended human dose (based on human equivalent dose comparison). In this study, which was conducted in pigmented rats, intravenous (bolus) administration of fosdenopterin for three consecutive days followed by ultraviolet radiation (UVR) exposure resulted in dose-dependent cutaneous skin reactions (erythema, edema, flaking, and eschar) and ophthalmic and histopathologic changes indicative of phototoxicity [see Warnings and Precautions (5.1)].

17 PATIENT COUNSELING INFORMATION
Advise patients/caregivers to read the FDA-approved patient labeling (Instructions for Use) and complete the treatment logs as appropriate.

Photosensitivity
Advise patients and/or caregivers of the potential for photosensitivity reactions and to ensure that the patient avoids or minimizes exposure to sunlight and artificial UV light exposure (i.e., UVA or UVB phototherapy) during use of NULIBRY, uses broad spectrum sunscreen with high sun protection factor (patients 6 months of age and older), and wears clothing, a hat, and sunglasses that protects against sun exposure. Instruct patients/caregivers to seek medical attention immediately if the patient develops a rash or if they notice symptoms of photosensitivity reactions (redness, burning sensation of the skin, blisters) [see Warnings and Precautions (5.1) and Nonclinical Toxicology (13.2)].

To report SUSPECTED ADVERSE REACTIONS, contact Origin Biosciences, Inc. at 1-888-55BRIDGE (1-888-552-7434) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

NULIBRY.com
NULIBRY is a trademark of Origin Biosciences, Inc.
Origin Biosciences is a member of the BridgeBio family.
©2021 Origin Biosciences, Inc. All rights reserved. US-NUL-2100003 03/21
Use of naso-/orogastric tubes in the Neonatal Intensive Care Unit (NICU) is very commonplace. However, they are not without possible complications and challenges. One that has gotten recent discussion and action is the risk of tubing misconnection. The Global Enteral Device Supplier Association (GEDSA) made the recommendation some time ago for manufacturers and end-users to transition to the standard enteral design of ENFit. This design prevents the accidental connection of intravenous (IV) or other tubing to a feeding tube, or feeding tubing to IV or other tubing.

In the process of transitioning to the new design, one issue that has arisen is the practice of giving oral medications via enteral tube, particularly low dose medications with a narrow therapeutic index. Due to the design change, the hub has a larger dead space and the syringe now has a moat around the connector as shown in Figure 1 that can serve to collect milk and medication. This results in two risks that deserve discussion: medication administration accuracy and infection.

Medication Administration Accuracy
Low risk oral medications have an industry established acceptable 10% dosing variance with some high risk medications limited to a 5% dosing variance (Johnson, Lee, Spooner, et al, 2011). In a study by O’Mara and Campbell (2019), dosing variance using the ENFit design in both oral and enteral use was evaluated. Enteral use refers to administration of medication via tubing while oral was giving the medication directly into the child’s mouth, often with use of an appropriate adapter and more often in the pediatric setting. These researchers found that dosing variance over 10% occurred twice as often with an ENFit low dose tip syringe as with an oral slip tip syringe (26.9% vs 12.9%). Additionally, they found that a greater than 5% variance happened significantly in either oral or enteral administration.

Since this is a common practice for many medications in neonatal and pediatric settings, it should be addressed from a clinical perspective to maintain medication safety/accuracy. High risk medications are not uncommon via enteral or oral method. This must be addressed before making the transition to an ENFit design system. Adapters for use with the ENFit syringe have been created and will be addressed further later in this article.

Another issue with the ENFit design when giving medications orally (directly into the mouth) is that the ENFit hub is quite large for many neonatal patients. This can result in trauma to the mouth. Therefore, an adapter or alternative method of administering medications to an infant must be considered. One may be to use the adapter and another may be to administer medications with a feeding via bottle. Oral-only tips still exist as alternatives to the ENFit design and may be an option when delivering medication orally. The use of adapters creates potential for dosing inaccuracy. The adapter has a long tip (Figure 2), making it convenient for giving medications into the mouth but also increases the dead space leading to loss of medication. This, too, may increase the dosing variance more than the acceptable 5-10%.

Some suggestions are to establish clinical guidelines in your institution between clinical areas where these may be used and pharmacy to address when and how the adapters will be used. Larger volumes of medications will result in less percentage loss,
methods were quite onerous with one containing 17 steps and the presence of visible residue in the connector. The cleaning of this area of the connector. The outcome of the study was based on the evaluation of two different cleaning methods to remove residue in the feeding tube. Lyman et al (2020) used such as q-tips, toothbrushes, and gauze. Lyman et al (2020) examined 129 feeding tubes from four different neonatal units. They found that 70% of these tubes were colonized with Enterobacter, Serratia marcescens and Klebsiella within 48 hours of insertion. These studies were done prior to the implementation of the ENFit connector, did not report the frequency of tube disconnection/interruption nor whether enteral medications were administered via the feeding tube.

Other more recent studies have evaluated and compared bacteria found in the feeding tube and that found in the infant's stool. Taft et al (2019) sampled portions of the feeding tube, residual fluid in the tube and infant stool from 47 infants. The purpose of this study was to evaluate differences in colonization of the feeding tube at various positions such as in the esophagus vs in the stomach. Previous studies have shown that the microbiome in the esophagus is different than in the stomach (Hunt and Yaghoobi, 2017). Furthermore, bacteria found in the stomach and stool of infants with feeding tubes in place are known to carry antimicrobial resistant genes (Ogrodzki et al, 2017). Taft et al (2019) found that organisms cultured from all levels of the feeding tube were similar and were reflected in the infant's stool samples, demonstrating that bacteria in the tube reflects that in the gut.

Increased rates of feeding intolerance, poor weight gain, meningitis and necrotizing enterocolitis have been associated with gastric tube contamination (Mehall et al 2002a; Alkeskas et al, 2015).

Various practices can impact risk for feeding tube contamination. These might include how the tube is handled prior to and during insertion, flushing the tube after feedings to prevent milk staying in the tube for an extended period of time and maintaining a “closed system” as much as possible (Beauman & Bowles, 2018), Keeping the tube closed when not in use may aid in preventing pathogenic bacteria from entering gastrointestinal system and potentially colonizing and/or infecting the infant.

Specific to the ENFit design, the male hub of the ENFit device contains a moat around the connector. This may get contaminated with milk and medications during connections and disconnections. Industry has created various devices to use in cleaning this area while other available items are also used such as q-tips, toothbrushes, and gauze. Lyman et al (2020) evaluated two different cleaning methods to remove residue in this area of the connector. The outcome of the study was based on presence of visible residue in the connector. The cleaning methods were quite onerous with one containing 17 steps and the other 9 steps. Each method was performed using either a firm-bristled toothbrush or commercially available cleaning brush designed to clean the ENFit connector. They found that the more intense method of cleaning (17 steps) resulted in the absence of visible residue and did not find any difference between use of the toothbrush or commercial brush. The concern presented by these researchers was more about the potential for adherence of the connector such that it could not be disconnected due to buildup of residue. The residue was not cultured nor were cultures taken before or after cleaning. There is no evidence that these cleaning methods decrease the risk of infection/contamination of the tube, something that is much more important in the neonatal population than any other. This study did not evaluate the frequency of cleaning that is needed, likely dependent on an individual patient and how the tube is used. In addition, taking care to avoid spillage into the moat when a syringe is connected will decrease the risk of contamination/overgrowth of bacteria in this area as well as potentially decreasing the need for cleaning. Lyman et al (2020) still recommend that cleaning take place at regular intervals, even if no visible residue is present.

Medication Delivery
Traditionally, pharmacy has used slip tip oral-only syringes. These work fine and are made such that they will not connect to an intravenous line. The use of these syringes for medications delivered in unit dose from the pharmacy is still acceptable. If the medication is to be delivered directly into the infant’s mouth or a bottle, as are most oral medications in the NICU, they work great. If, however, they need to be connected to a ENFit feeding tube for delivery, they do not connect. Some manufacturers have created a device that allows this connection. This device will create dead space so some practice changes are necessary. Nurses may attach this device to a slip tip oral syringe, connect to the feeding tube and administer the medication. This should be followed by a small flush of air or feeding to ensure the desired amount of medication is administered to the patient.

Conclusion
The change to the ENFit oral connector has been a challenging one but the purpose of preventing tubing misconnections is important in clinical practice. We know that changing practice by simply saying to remember to do something, to do better at something is less likely to bring this about. The only effective method is to make it impossible to be done incorrectly! The ENFit system accomplishes this.

However, as with any change, there are unintended consequences that must be addressed. The effect on administration of medications, particularly low dose medications as is common in the NICU, has created challenges. These challenges can be met with the available supplies but require planning and education.

References


The Benefits of Personalized Lung Protection and Weaning Solutions

In this feature, Neonatal Intensive Care interviews clinicians and healthcare providers about the actual application of specific products and therapies. This interview is with Eric Honroth, Getinge President, North America.

Can you tell us about the recent clearances your company has received?
In April of this year, we received FDA Class II 510(k) clearance for 4.1 software upgrades for the Servo-u and Servo-n ventilator systems and clearance to introduce the next generation of the Servo-u MR ventilator system into the US market.

Mechanical Ventilation—why is this important?
Mechanical ventilation is a well-established life supporting treatment for the lung-compromised patient. In the United States, it is estimated that over 300,000 patients receive mechanical ventilation each year (excluding COVID-19 in 2020/21). Mechanical ventilation is a life supporting treatment delivered to patients who suffer from a wide spectrum of acute respiratory failure (ARF). The ventilator functions to allow the patient to heal and recover. Over time, we have come to understand that life supporting, mechanical ventilation over extended periods of time can have an adverse effect on the lungs. Ultimately, the goal is to assist the patient when needed and to help improve clinical care.

What are the challenges in the ICU and, in particular, mechanical ventilation?
Mechanical ventilation is life supporting in patients with respiratory failure but may lead to lung injury. Lung injury can be impacted by the settings of the mechanical ventilator resulting in potential consequences including:
• Ventilator acquired pneumonia (VAP)
• Ventilator induced lung injury (VILI) including atelectrauma, volutrauma, barotrauma, and biotrauma
• Ventilator induced diaphragmatic dysfunction (VIDD)
• Myotrauma

Recent clinical studies suggest that many ventilators lack effective bedside decision support tools. It is a problem that results in protective strategies being delayed or inconsistently applied. Ultimately, this can harm the patient and worsen the outcome.1,2,3

Can you tell us about the benefits of personalized lung protection and weaning solutions? How does this help patients?
Getinge is a leader when it comes to high acuity patients and mechanical ventilation.

Our Servo family is tailored to the acute care segment. We constantly strive to innovate our products and advance the markets that we serve. Servo-u, Servo-n, and Servo-u MR with system version 4.1 give clinicians many options for personalized lung protection and weaning.

Our goal is that clinicians can deliver the right protection, for each patient, at the right time with a comprehensive toolkit for clinicians to make decisions and plan of care. The main toolkit includes:
• Servo Compass for easy-to-see plateau driving pressure or tidal volume per predicted body weight (VT/PBW) monitoring.
• Transpulmonary pressure monitoring to provide guidance on the relationship between airway and transpulmonary pressure.
• Open Lung Tool to assess lung mechanics and gas exchange.
• Finally, Automatic recruitment maneuvers Auto SRM and Auto RM. Auto SRM is an automatic workflow for Stepwise recruitment maneuvers based on the Open Lung approach and is unique to Getinge.

In terms of weaning support, most clinicians are familiar with NAVA/Edi monitoring and its potential to activate the diaphragm and protect the lungs. In addition to PRVC and High Flow Therapy, clinicians can now have access to Heliox therapy to help reduce the work of breathing for patients with obstructed asthma.

Do the software upgrades have any benefits for the clinician?
The 4.1 software integrates major respiratory therapy enhancements for all patient categories—adults, pediatrics, and neonates. We have a legacy of more than 50 years of close collaboration with intensive care clinicians worldwide, working together to develop ways to improve the software offerings of the Servo ventilators. We always ensure we are updating the base software with new features and then layering in additional purchasable upgrades like the Automatic Recruitment maneuvers, transpulmonary pressure monitoring, and Heliox therapy.
One of the software options includes Automatic Stepwise Recruitment maneuver — why is this important for patients and clinicians?
The Open Lung Tools includes three new and different tools: Automatic Stepwise Recruitment maneuvers (Auto SRM), Automatic Recruitment maneuvers (Auto RM), and open lung trends, a manual recruitment maneuver tool. We are very excited about the Automatic Stepwise Recruitment maneuvers, automatic lung recruitment with PEEP titration. Auto SRM was designed to create a standardized workflow that optimally divides the workload between the clinician and the ventilator. Pressures are incrementally increased to reduce the occurrence of hemodynamic compromise, and alarm limits are automatically adapted. The tool guides the clinician through recruitment, decremental PEEP titration, re-recruitment, and post-recruitment. With Auto SRM, the clinician will find the right PEEP and right driving pressure, and all of this is automatic.

The Automatic recruitment maneuver allows for quick recruitment after patient disconnection, suction, or surgery, keeps recruitment settings used in Auto SRM. It also provides an opportunity to delegate recruitment when few physicians are available (during night shifts), a post-recruitment summary with color-coded results, and a shortcut to open lung tool trends.

We see the clearance includes Heliox therapy. Can you tell us more about what Heliox therapy is and how it benefits patients?
Servo-i users will be familiar with Heliox, and we are excited to offer Heliox now as part of the Servo u/n ventilators. It is yet another tool that clinicians can use to support advanced personalized ventilation. Heliox has long been used as an adjunctive therapy to overcome airflow-obstruction disorders. In combination with Servo’s integrated Aerogen nebulizer, it is often used as an adjuvant treatment while waiting for the onset of conventional pharmacological treatments. It provides a smoother airflow for patients with obstructive lung disease such as exacerbated asthma and COPD, reduces airway resistance due to laminar flow, cost-efficient due to low gas consumption, can be combined with all ventilator modes, invasive to NIV, High Flow therapy, and nebulization. It is easy to switch from Heliox to air and back.

What other kinds of lung protection functionality does the new software have?
Transpulmonary pressure monitoring, including key parameters for assessment of lung stress during controlled and spontaneous ventilation, complements the lung protective toolkit, which was designed to optimally divide the cognitive workload between the clinician and the ventilator. Transpulmonary pressure monitoring validates balloon positioning and includes a diagnostic view including esophageal (Pes) and transpulmonary (PL) pressure waveforms. We wanted clinicians to have an intuitive tool that provides guidance on the relationship between airway and transpulmonary pressure. It is one additional tool for clinicians to use as part of a personalized and lung protection strategy.

What about the base software — any enhancements there?
There have been several additional enhancements to the Servo base software, version 4.1, including the addition of the Stress index for lung mechanics monitoring (Servo-u & Servo-u MR only) and the inclusion of PEEP 0 (ZEEP), and several enhancements to the user interface.

Can you tell us more about the Servo-u MR system and how it might make it easier to monitor patients on ventilators?
The Servo-u MR is the newest member of the Servo family. It has been designed to provide all the key features of a Servo-u with special adaptations for the MR room. Positioning the ventilator in an MRI room can be a real challenge. We have included a magnetic field indicator with visual and audible alerts to help guide the unit to a safe position. In addition, the Servo-u MR features a visible auto-lock handle. When depressed, the wheels unlock, allowing the unit to be moved. As soon as your hand leaves the handle, it will automatically lock up all four wheels, stopping the unit.

We have also enhanced some existing features. Our software interface, a key feature, is now housed in a large 15” screen that can be tilted and rotated for a flexible view from any angle.

Now, with Distance view with Servo Compass, the operator can see at a glance from the control room all the important parameters, and the system will alert you of any deviation from set targets.

Can you tell us more about the Servo Family Range?
With the introduction of Servo-air last year and Servo-u MR to the Servo Family, you can be confident, no matter where in the hospital you are, that you have access to the trusted Servo technology. The Servo-u was designed to enhance user confidence in tailoring treatments to the individual patient’s condition. This means more patients in all phases of ventilation — controlled, supported, non-invasive, and during spontaneous breathing trials — can benefit from advanced lung protective strategies.

The Servo-n is our neonatal/pediatric ventilator created to help provide vulnerable patients with the support they need while protecting the lungs, brain, and other developing organs. Sensitive and responsive, Servo-n compensates for variable leakage in both invasive and non-invasive modes of ventilation. Servo-n can deliver tidal volumes as low as 2ml in patients as small as 0.3kg and includes optional hot-wire flow sensor technology to both trigger and measure pressure and flow at the patient interface.

The recently introduced Servo-air launched in Oct 2020 is a turbine-driven ventilator with a hot-swappable battery backup, making it perfect for intra-hospital transport without requiring wall gas or power outlets. It can be easily lifted and moved with patients within the facility. Finally, rounding out the family offerings is the NEW conditional, Servo-u MR, designed to ventilate all patient categories during MR scanning, from invasive and non-invasive ventilation to high-flow therapy.

It has been quite a year for mechanical ventilation. Yes, it really has. In addition to the introduction of the Servo-air, Servo-u MR, and the updated SW 4.1, there have also been a few very impactful studies around NAVA. We have additional information about those on our website, www.getinge.com. We are celebrating 50 years as a leader in the mechanical ventilation market globally and are proud of our legacy of driving innovation within the space. We are really looking forward to many more years of helping to shape the future of mechanical ventilation through continued collaboration with intensive care clinicians and further innovation.
References


4 Vs. Servo-i
Personalized lung protection

The right protection, for each patient at the right time.

Servo ventilators offer a complete toolkit for personalized lung protection, enabling you to detect risks early and support timely and consistent implementation of protective ventilation strategies personalized for each patient. Powerful tools such as Servo Compass, Transpulmonary pressure monitoring, and Automatic Recruitments with Open Lung Tool help you utilize advanced protective strategies.

Built on over 50 years of close collaboration with intensive care clinicians around the world, Servo ventilators offer clinical innovation, a focus on patient safety, and a modular, intuitively designed package.

www.getinge.com
Preterm birth is the leading cause of long-term neurodevelopmental disability, impacting approximately 500,000 infants in the US annually, at an estimated cost of $26 billion dollars per year. When a baby is born too soon, normal intrauterine growth and development is interrupted; thrusting the infant into a foreign and high stress environment that negatively affects the brain, growth, and development. Although advances in neonatal care for preterm infants have greatly increased the chances for survival, survival is not the only anticipated outcome. Helping pre-term and ill infants to thrive by reducing threats to long-term physical, psychological, and social well-being is equally as important.

Preterm babies are at risk for serious health problems, including birth defects, neurodevelopmental delays, and complications of care such as cranial deformities and pressure injuries. Consequently, improper or inadequate neonatal positioning can negatively affect sleep, brain and musculoskeletal development, neurobehavioral organization, neuromotor and physiologic functioning, and feeding. Although a number of advanced technologies aim to reduce harm, therapeutic developmental positioning remains a fundamental catalyst for optimal outcomes in the care of premature and ill neonates.

Effective positioning provides a number of benefits to the preterm and ill infant. It reduces toxic stress, facilitates security and self-control, and improves sleep. Proper positioning can also improve brain, neuromotor, and musculoskeletal development, physiologic function and stability, and thermal regulation, and preserve skin integrity. Infants who are contained also tend to be calmer, require less medication, sleep more, develop better, and gain weight more rapidly.

Z-Flo™: The New Standard
While most healthcare providers in the NICU understand the value of positioning to the preterm and ill infant’s well-being, process and product standardization are rare. This results in variable and often sub-optimal clinical outcomes, waste, and unnecessary costs. Standardizing positioning practices with a one product solution can optimize neurodevelopment outcomes, while saving healthcare providers and their organizations time and money. Mölnlycke’s unique, patented Z-Flo™ Fluidized Positioner is that solution!

Z-Flo™ Fluidized Positioners allow for customizable positioning and have been shown to meet the unique positioning needs of premature and ill infants. In addition to an infinitely customizable nest, Z-Flo allows for individualized positioning that promotes flexion, midline orientation, and containment for comfort, sleep positively affecting flexor tone, symmetrical movement, head shape, range of motion, pressure injury prevention, and overall development.

A Solution for Every Challenge
Sleep deprivation in premature infants can result in loss of brain plasticity, smaller brains, altered learning and long-term behavioral challenges. A study of conformational fluidized positioning with Z-Flo™ versus standard positioning, infants calmed more easily, showed reduced wakefulness, and were observed to sleep better. Even neonates with surgical and gastrointestinal complications showed higher sleep efficiency.

Low birth weight and younger gestational age puts infants at increased risk for intraventricular hemorrhage. Although the cause of these brain bleeds is multifactorial, seemingly benign care activities such as head turning is a contributing factor. Evidence and expert opinion support the recommendation of midline head positioning for premature infants to reduce the risk of intraventricular hemorrhages. Z-Flo™ Fluidized Positioners can be molded to facilitate effective and sustained midline head positioning.

Premature and ill infants are also at high risk for pressure injuries due to immature skin, decreased mobility, head-body disproportion, and medical devices. Hospital acquired pressure injuries increase healthcare cost and may result in litigation, reduced reimbursement, and government penalties. Z-Flo™ Fluidized Positioners offload bony prominences, including the occiput to prevent pressure injuries. They can also be molded to support and align medical tubing and lines, to minimize torque and tension that could cause pressure injuries, skin tears, and other skin injuries.

Premature and ill patients may also experience long periods of immobility due to external monitoring, therapeutic equipment, and physiologically instability. This can lead to prolonged and unrelieved pressure on the cranial bones, resulting in positional plagiocephaly and other cranial deformities. In addition to parental anxiety, cranial deformities can negatively impact the patient’s long-term quality of life and have serious implications including developmental delays, disfigurement, and behavioral
THIS IS HOW YOU PUT A NICU PATIENT IN A POSITION TO THRIVE.

In the NICU, little things are big things. That’s why the team works around the clock to watch over, nurture and provide comprehensive care for every infant. You’ll reposition the baby 8 to 12 times a day because you know it promotes development—physically and even psychologically.¹ And that’s where we come in. Our Z-Flo™ Fluidized Positioners continue the nurturing when you’re not at the bedside. They allow you to custom-mold a shape to fit the infant’s body for optimum comfort and protection. And they hold shape so infants stay in position, feel secure and get the sleep they need.


Get the complete story at www2.molnlycke.us/zfloneonatal

Möllycke® Z-Flo Fluidized Positioners for Neonatal also helps offload bony prominences while maintaining neutral body alignment and reduces risk of skin tears and pressure on ultra-sensitive skin.

Get the complete story at www2.molnlycke.us/zfloneonatal
abnormalities. Cranial deformities often require costly and lengthy management and result in litigation, government penalties, and negatively affect hospital metrics.\(^9\) Prevention is key since the human cost and financial aspects of treatment for cranial orthoses alone can range from $2000 to $4000, a cost rarely covered by insurance.\(^9\) Z-Flo™ has been shown to facilitate optimal head shape and decrease cranial deformities in preterm infants.\(^7\)

**The True Cost**

The average length of stay for preterm infants is 21 days at an average cost of stay for preterm infants of $121,000 ($5,600/day) with lower gestational ages.\(^11\) Risk reduction of pressure injuries, avoidance of positional injuries, and optimized sleep can lead to reduced total cost of care for the hospitalized neonate. The added cost of corrective therapies and medical equipment for unintended consequences of care often fall on the parents following hospital discharge, creating a continued financial burden, in addition to the stress of caring for a preterm infant long after leaving the NICU.

A standardized approach to positioning the pre-term and ill infant with Z-Flo™ can have far-reaching benefits for infants, their caregivers, and the healthcare organization, as a whole. By utilizing a standardized approach to positioning with the Z-Flo™ Fluidized positioner, hospitals can meet the needs of all preterm and ill infants for containment, midline positioning, and pressure redistribution with a singular product. Standardization of practice with Z-Flo™ can help reduce the incidence of complications of care and adverse outcomes, while streamlining practice to improve clinical decision making; optimizing results and cost savings through waste reduction and the avoidance of patient harm.

**References**

5. Barr, J. (2014). The trials and tribulations of the introduction and implementation of new positioning products in the NICU. Overland Park Regional Medical Center: Poster Presentation
Incidence of Urinary Tract Infection in Neonates with Significant Indirect Hyperbilirubinemia of Unknown Etiology

Ahmed Mahrous Kamal Baz¹, Osama Abd El-Fattah El-Agamy² and Ashraf Mohamed Ibrahim³

Abstract
Background: Indirect hyperbilirubinemia is frequently encountered during neonatal period. Although it has different causes, in some cases it can’t be explained. Previous studies have illustrated that jaundice could be a major sign of urinary tract infection (UTI) in neonates.

Aim of the work: We aimed to determine the association between UTI and significant unexplained neonatal indirect hyperbilirubinemia.

Methods: This prospective controlled study was performed on 150 neonates divided in two groups (100 as cases and 50 as controls) to investigate the incidence of UTI in neonates with significant unexplained hyperbilirubinemia. Urine sample was obtained using urine catheterization technique from neonates and full urine analysis was done and cases with pyuria had urine culture to confirm UTI. Immediate renal ultrasonography (USG) was performed for neonates with UTI.

Results: UTI incidence was 11% in cases while none of neonates in control group had UTI with statistical significance between cases and controls (P value < 0.05). The most common (36.4%) pathogen was Escherichia coli. Posterior urethral valve with mild hydronephrosis was diagnosed in 18.2% of UTI positive patients by renal ultrasonography.

Conclusion: In neonates with unexplained indirect hyperbilirubinemia, UTI should be considered as a pathological cause.

Introduction
Hyperbilirubinemia is frequent in newborns. In some newborns, total serum bilirubin doesn’t reach pathological levels while in others it may exceed physiological levels and requires treatment. Many well-known causes could be detected during routine investigation of neonates with significant hyperbilirubinemia while in others it may remain unexplained.¹

Neonatal jaundice is mainly physiological and 60% of neonates have it. A small number of those neonates have pathological problems like ABO or Rh incompatibility, hepatic impairment, systemic infection or metabolic disease. In neonates with Urinary Tract Infections (UTIs), jaundice could be an early sign.²

One of the causes of prolonged jaundice is UTI. UTI investigations have been included in routine workup in neonates with prolonged jaundice. There was high incidence of UTI in neonates who developed jaundice after first week of neonatal age in study performed by Garcia and Nager. Ghaemi et al. also observed equal incidence rate of UTI in neonates with prolonged jaundice and neonates with febrile illness with matched ages. On the contrary, it was observed by Omar et al. and Bilgen et al. that asymptomatic neonates with UTI developed jaundice during the first week of neonatal age. Therefore, besides investigating UTI in prolonged jaundice, it was recommended that testing for UTI should be included in the workup of neonates who develop jaundice in early neonatal period.³

The aim of this study was to detect if UTI is a significant cause of unexplained indirect hyperbilirubinemia in jaundiced neonates who require treatment and should it be included in routine workup of those neonates.

Methods
This analytical case-control study was conducted on 100 neonates (43 males & 57 females) at NICU in Kafr Elsheikh University Hospital with a gestational age greater than 35 weeks with significant unexplained indirect hyperbilirubinemia as cases and on 50 matched neonates (25 males and 25 females) without hyperbilirubinemia as controls. Cases were recruited during study period from January 2019 till February 2020.

Neonates with hemolytic diseases, glucose-6-phosphate dehydrogenase (G6PD) deficiency, neonatal sepsis, polycythemia, with direct hyperbilirubinemia, hypothyroidism and metabolic diseases were excluded.

All newborns were subjected to careful history taking including mode of delivery, full maternal history, maternal blood grouping for detection of incompatibility, family history of jaundice and history of G6PD in a family member. Full clinical examination was done with performing the following investigations serum total and direct bilirubin, full blood count, reticulocyte index and peripheral blood smear, coomb’s test (direct), C reactive protein (CRP), urea and creatinine, liver functions, confirmed urinary tract infection were investigated by renal ultrasonography to exclude congenital anomalies.

¹Neonatology Unit, Pediatrics department, Kafrelsheikh Faculty of Medicine, Ibrahim Moghazy st. 21, Kafrelsheikh 33511, Egypt. ²Kafrelsheikh Faculty of Medicine, Kafrelsheikh, Egypt. ³Neonatology Unit, Pediatrics department, Tanta Faculty of Medicine, Tanta, Egypt.
Phototherapy is using light irradiance more than 30 microW/cm²/nm detected by radiometer.

Results

A sum of 150 neonates presented to the NICU fulfilling criteria of case and control groups. Of the 100 neonates of cases group, 57 were female, and 43 were male. Of the 50 neonates of control group, 25 were males and 25 were females. All males were uncircumcised. As illustrated in (Table 1), no significant statistical difference between case and control groups was observed regarding demographic data.

Sixty-five percent of case group were exclusively breastfed, 20% were formula fed, and 15% depended on both types of feeding. Fourteen neonates were treated with intensive phototherapy; the rest were treated with conventional phototherapy. None of the studied neonates had fever. Laboratory data of case and control groups are illustrated in (Table 1). UTI was confirmed in eleven neonates of case group while no case in control group had confirmed UTI. The most common microorganisms in urine culture was Escherichia coli (36.4%) followed by acitenobacter bacilli (27.3%) (Table 2).

Nineteen percent of mothers of case group had history of maternal infection, 11% had UTI and 8% had PROM. (Table 3) illustrates association between results of urinary culture and some laboratory tests and clinical data. The comparative phototherapy type in case group of the UTI positive neonates (group A) vs UTI negative neonates (group B) are illustrated in (Fig. 1). Abdominal ultrasonography (USG) with focus on kidney and bladder was performed to cases with positive culture results during hospitalisation which diagnosed two patients (18.2%) to have posterior urethral valve with mild hydronephrosis (Fig. 2).

Discussion

Jaundice is considered one of the most common problems in neonates. About 60% of full term infants develop jaundice. Indirect hyperbilirubinemia is common and is related to a spread of physiologic and pathologic conditions. Neonates with UTI may present only with jaundice. UTI investigations have been included in routine workup of jaundice. Although investigating for UTI in neonates with significant unexplained indirect hyperbilirubinemia remains controversial. Hence the aim of this study was to evaluate UTI among neonates with significant unexplained indirect hyperbilirubinemia.

This study indicated the incidence of UTI in our studied cases was 11% of jaundiced neonates while no case in control group diagnosed with UTI with significant statistical difference between 2 groups (P value < 0.05). In previous studies, the

**Table 1** Association between case and control groups according to some demographic data and laboratory values

<table>
<thead>
<tr>
<th></th>
<th>Cases (n = 100)</th>
<th>Control (n = 50)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age on admission</td>
<td>118.80 ± 51.66</td>
<td>119.04 ± 52.66</td>
<td>0.976</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>3.13 ± 0.34</td>
<td>3.13 ± 0.34</td>
<td>1.00</td>
</tr>
<tr>
<td>Total bilirubin (mg/dl)</td>
<td>17.90 ± 1.71</td>
<td>21.88 ± 0.87</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td>Direct bilirubin (mg/dl)</td>
<td>0.68 ± 0.34</td>
<td>0.40 ± 0.22</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td>Hemoglobin (gm/dl)</td>
<td>15.42 ± 1.42</td>
<td>15.61 ± 1.59</td>
<td>0.478</td>
</tr>
<tr>
<td>Reticulocyte count (%)</td>
<td>1.70 ± 0.82</td>
<td>1.70 ± 0.82</td>
<td>0.984</td>
</tr>
<tr>
<td>Urea (mg/dl)</td>
<td>16.73–4.27</td>
<td>16.91–4.29</td>
<td>0.775</td>
</tr>
<tr>
<td>Creatinine (mg/dl)</td>
<td>0.40–0.22</td>
<td>0.39–0.21</td>
<td>0.732</td>
</tr>
</tbody>
</table>

p: p value for comparing between the studied groups

*: statistically significant at p ≤ 0.05

Figure 1. Bar chart comparing neonates in case group according to phototherapy type where Group a represents newborns with indirect hyperbilirubinemia and UTI confirmed by urine culture and Group b represents newborns with indirect hyperbilirubinemia but don’t have UTI or have pyuria. Conventional phototherapy is using light irradiance of 25-30 microwatts per square centimeter per nanometer (microW/cm²/nm) in the 430-490 nm band. Intensive Phototherapy is using light irradiance more than 30 microW/cm²/nm detected by radiometer.
incidence of UTI in jaundiced neonates has ranged from 5.8 to 21%. Ghaemi et al.7 had a prospective study which reported UTI incidence of 5.8% in jaundiced neonates. The highest (21%) incidence of UTI was reported in a study done by onze et al.3

In our study there was no statistical difference between incidence of UTI between males and females as six out of 11 were females while five were males. Chen et al.8 reported similar results as UTI incidence in males was 41.7% while in females was 58.3%. Another retrospective study done by Omar et al.4 stated that UTI in males was 59.4% while in females was 40.6% with no statistical difference. On the other hand, Cleper et al.9 reported that the percentage of UTI in females was 6 times less than in males and the percentage was also 3 times higher in males in the study of Bilgen et al.2 Forty-five out of 100 in case group had irrelevant family history of jaundice with no statistical difference between 2 groups.

Blood culture in all cases confirmed to have UTI by urine culture was negative. This disagrees with study done by Bahat Ozdogan et al. who found that of UTI positive jaundiced neonates, 6.2% had documented bacteremia.10 The comparison between the positive & negative groups regarding history of maternal infections showed there was statistical significant difference between the two groups (p-value < 0.05).

As regards the most common isolated organisms, three out of 11 (36.4%) of positive cases were caused by Escherichia coli infection, 27.3% (3 out of 11) caused by acinetobacter bacilli. E. coli was the most common organism in studies of Chen et al.8 and Bahat Ozdogan et al. showed that E. coli was the causative organism in 50% of cases10 while Omar et al. found in their study that the most of isolated organisms were klebsiella (46.7%), and E. coli (37.5%).3

Our data showed that out of 11 cases, there were two cases diagnosed to have a posterior urethral valve (PUV) with mild hydronephrosis. The two cases had no signs of sepsis (e.g., fever, lethargy, or poor feeding), and all inflammatory markers

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Microorganisms isolated by urine culture in group A (newborns with indirect hyperbilirubinemia and urinary tract infection confirmed by urine culture) (n = 11)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gram positive organisms</strong></td>
<td>Number</td>
</tr>
<tr>
<td>Staphylococcus aureus</td>
<td>1</td>
</tr>
<tr>
<td>Enterococci</td>
<td>1</td>
</tr>
<tr>
<td><strong>Gram negative organisms</strong></td>
<td></td>
</tr>
<tr>
<td>Gram Negative Bacilli E. coli</td>
<td>4</td>
</tr>
<tr>
<td>Gram Negative Bacilli Acinetobactar</td>
<td>3</td>
</tr>
<tr>
<td>Gram negative bacilli (Klebsiella Pneumonia)</td>
<td>2</td>
</tr>
</tbody>
</table>

**Table 3** Comparison between cases confirmed to have UTI and negative cases in case group according to some clinical and laboratory variables

<table>
<thead>
<tr>
<th>Variable</th>
<th>Urinary Tract Infection</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group A (Positive) (n = 11)</td>
<td>Group B (Negative) (n = 89)</td>
<td>P value</td>
</tr>
<tr>
<td><strong>Mean ± SD.</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age on admission (hours)</td>
<td>120.0 ± 41.57</td>
<td>118.65 ± 52.97</td>
<td>0.674</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>3.01 ± 0.20</td>
<td>3.14 ± 0.36</td>
<td>0.255</td>
</tr>
<tr>
<td>Total bilirubin (mg/dl)</td>
<td>18.09 ± 1.45</td>
<td>17.87 ± 1.74</td>
<td>0.468</td>
</tr>
<tr>
<td>Direct bilirubin (mg/dl)</td>
<td>0.67 ± 0.33</td>
<td>0.68 ± 0.34</td>
<td>0.934</td>
</tr>
<tr>
<td>Hemoglobin (gm/dl)</td>
<td>16.05 ± 1.23</td>
<td>15.34 ± 1.43</td>
<td>0.132</td>
</tr>
<tr>
<td>Reticulocyte count (%)</td>
<td>2.64 ± 1.14</td>
<td>2.4 ± 1</td>
<td>0.454</td>
</tr>
<tr>
<td>Urea (mg/dl)</td>
<td>17.19 ± 5.13</td>
<td>16.67 ± 4.18</td>
<td>0.639</td>
</tr>
<tr>
<td>Creatinine (mg/dl)</td>
<td>0.55 ± 0.28</td>
<td>0.39 ± 0.20</td>
<td>0.081</td>
</tr>
<tr>
<td>**No.</td>
<td>%</td>
<td>No.</td>
<td>%</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>5</td>
<td>45.5</td>
<td>38</td>
</tr>
<tr>
<td>Female</td>
<td>6</td>
<td>54.5</td>
<td>51</td>
</tr>
<tr>
<td>Maternal infection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>4</td>
<td>36.4</td>
<td>77</td>
</tr>
<tr>
<td>UTI</td>
<td>5</td>
<td>45.5</td>
<td>6</td>
</tr>
<tr>
<td>PROM</td>
<td>2</td>
<td>18.2</td>
<td>6</td>
</tr>
<tr>
<td>Maternal history of chronic disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non</td>
<td>8</td>
<td>72.7</td>
<td>62</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1</td>
<td>9.1</td>
<td>9</td>
</tr>
<tr>
<td>Hypertension</td>
<td>2</td>
<td>18.2</td>
<td>18</td>
</tr>
</tbody>
</table>

FE Fisher Exact, MC Monte Carlo
p: p value for comparing between the studied groups
*Statistically significant at p ≤ 0.05
Group A: Newborns with indirect hyperbilirubinemia and UTI confirmed by urine culture
Group B: Newborns with indirect hyperbilirubinemia but don’t have UTI or have pyuria
were negative; this may attribute the bilateral hydronephrosis to mechanical obstruction by PUV rather than UTI. The guidelines of American Academy of Paediatrics (AAP) advocate doing US in all > 2-month-old infants with UTI accompanied by fever but there are no recommendations for neonates with UTI. Our study didn't document a significant portion of USG abnormality neonates with UTI. However, in study done by Bahat Ozdogan et al., he found that there was abnormal finding in 28.1% in renal USG of jaundiced neonates confirmed to have UTI.  

One limitation of the study is that not all the studied cases and controls have had urine culture; we performed screening for all neonates included in the study using urine analysis (including performing leukocyte esterase test (LE) and nitrite test) and microscopic examination for the presence of pyuria. This limitation was due to NICU and microbiology laboratory local policy, which restricts performing urine culture only to cases with sepsis (which was one of the exclusion criteria in the study) or cases with abnormal urine analysis or pyuria. However, obtaining urine samples using aseptic urinary catheterization technique increased the specificity of these investigations; also using aggregate urine analysis (the presence of any LE, nitrite, or pyuria > 5 WBCs/HPF) increases the sensitivity for UTI detection in infants less than 60 days of age to 99.4% as indicated in a study done by Tzimenatos L et al. Also, the absence of pyuria can help in differentiation true UTI from asymptomatic bacteriuria.  

UTI in neonatal period has many nonspecific symptoms like fever, lethargy, vomiting, anorexia, diarrhea, weight loss, changes in urine characters and jaundice. So, neonates with UTI could present early with jaundice. It remains unclear how UTI is related to jaundice in neonates but there are some explanations that need further evaluating studies. Of these explanations is hepatocellular injury that may be caused directly circulating microorganisms that caused UTI or by their circulating endotoxins. On the other hand, jaundice may be the cause of UTI through making neonates more prone to infections by decreasing the bactericidal activity of their serum as reported in study done by Cisowska et al.  

Conclusion  

From the previous discussion, we can come to the conclusion that UTI may be one of causes of neonatal unexplained indirect hyperbilirubinemia. Also, it was found that there is a positive correlation between maternal infections and UTI in jaundiced neonates. Therefore, we can suggest that UTI investigations could be included in routine workup of neonates with unexplained indirect hyperbilirubinemia and good antenatal follow up with early treatment of maternal infections could prevent UTI in newborns.  

Authors’ contributions  

Ahmed Mahrous Baz performed the clinical examination, collected urine samples, did basic investigations and contribute in data interpretation, Osama Abdelfattah Elagamy formatted study design and contributed in results interpretation and discussion, Ashraf Mohamed Ibrahim did the statistical analysis and contributed in results interpretation and discussion. All authors have participated in drafting the manuscript, author A revised it critically. All authors read and approved the final version of the manuscript. All authors contributed equally to the manuscript and read and approved the final version of the manuscript.  

Funding  

The authors received no financial support for the research, authorship, and/or publication of this article.  

Availability of data and materials  

All data generated or analysed during this study are included in this published article [and its supplementary information files].  

Ethics approval and consent to participate  

The study followed the Principles of the Declaration of Helsinki.
and approved by the Ethical Review Committee of Kafrelsheikh University and informed written parental consent from all participants in the research.

References
Improving Critical Care in the NICU

By sharing your goals, we can help you address your toughest challenges

This is what drives us: To improve critical care by offering solutions that provide clinical and financial value in the NICU. That’s why Frost & Sullivan selected Dräger for its prestigious 2020 Global Ventilator Technology Innovation Leadership Award — citing our pioneering work to enhance patient safety and expedite recovery through innovative clinical strategies and continuous improvements in ventilation technology, as well as best-in-class services/support, training and continuing education.

Visit www.draeger.com/intensivecare to learn more.

Dräger. Technology for Life*
Circulating Tight-Junction Proteins Are Potential Biomarkers For Blood-Brain Barrier Function

E Axel Andersson, Carina Mallard and C Joakim Ek*

Abstract
Background: Neonatal encephalopathy often leads to lifelong disabilities with limited treatments currently available. The brain vasculature is an important factor in many neonatal neurological disorders but there is a lack of diagnostic tools to evaluate the brain vascular dysfunction of neonates in the clinical setting. Measurement of blood-brain barrier tight-junction (TJ) proteins have shown promise as biomarkers for brain injury in the adult. Here we tested the biomarker potential of tight-junctions in the context of neonatal brain injury.

Methods: The levels of TJ-proteins (occluding, claudin-5, and zonula occludens protein 1) in both blood plasma and cerebrospinal fluid (CSF) as well as blood–brain barrier function via 14C-sucrose (342 Da) and Evans blue extravasation were measured in a hypoxia/ischemia brain-injury model in neonatal rats.

Results: Time-dependent changes of occludin and claudin-5 levels could be measured in blood and CSF after hypoxia/ischemia with males generally having higher levels than females. The levels of claudin-5 in CSF correlated with the severity of the brain injury at 24 h post-hypoxia/ischemia. Simultaneously, we detected early increase in blood–brain barrier-permeability at 6 and 24 h after hypoxia/ischemia.

Conclusions: Levels of circulating claudin-5 and occludin are increased after hypoxic/ischemic brain injuries and blood–brain barrier impairment and have promise as early biomarkers for cerebral vascular dysfunction and as a tool for risk assessment of neonatal brain injuries.

Keywords: Biomarkers, Blood–brain barrier, Hypoxia/ischemia, Neonatal, Tight-junctions

Background
Neonatal encephalopathy is a syndrome characterised by neurological dysfunction presenting as e.g. seizures and respiratory difficulties.1,2 Neonates that are diagnosed with neonatal encephalopathy (NE) are, if they survive, at high risk of developing life-long and permanent neurodevelopmental disabilities.3 Although hypothermia has been shown to be a beneficial treatment under certain circumstances, since it has to be initiated within six hours and can only be implemented in some of the neonates, with a number needed to treat of around eight, novel or adjunctive treatments are needed.4,5 A key step in the development of new treatments is diagnostic tools enabling early diagnosis and/or monitoring of injury progression. The aetiology underlying brain injury in the newborn is complex and is likely to involve many factors, making early diagnosis very difficult.6 The most commonly used early clinical tools to assess neonatal NE include cord blood gas analyses,7 Apgar and Sarnat scoring systems.8 However, these methods have a low predictive value for the subsequent brain injury.9 The resulting brain injuries are typically visualised by advanced imaging methods such as MRI and CT-scans,10 techniques that are both expensive and have a relatively low availability, in terms of both equipment and skilled personnel, in many countries.11 This is important to note as it has been estimated that as many as 96% of neonates affected by NE are born in low- and middle-income countries.12 There is a clinical need for better and affordable diagnostics of neonatal brain injuries that would enable early risk assessment and intervention as well as monitoring of injury development. Putative biomarkers for neuronal damage following NE would be a valuable diagnostic tool to predict long-term outcomes but has the drawback that they are usually measurable only after the injury has manifested.13

The brain vasculature is a central factor in many human neonatal neurological disorders, such as intracranial haemorrhages and neonatal stroke,14 and the blood-brain barrier (BBB) is disrupted early in the disease process.15-20 A biomarker that reflects the state and function of the neonatal brain vasculature could be a powerful predictor for brain injury, considering that studies in rats have shown that the dysfunction of the BBB mirrors the severity of hypoxic/ischemic (HI)-injuries.15,16 Additionally, assessment of BBB function is of importance for the success of treatments that are directed at the brain. The capillary endothelial cells of the cerebrovasculature are connected by continuous complexes of tight-junction (TJ) proteins, which restrict passage between the brain and the bloodstream, thus maintaining the integrity of the BBB and function of the brain.21 Previous studies in adults have shown that TJ-proteins are shed from the BBB and cerebral vasculature and enters the circulation in a model of adult stroke in rats,22 in humans following stroke23 as well as after intracranial haemorrhage.24 Furthermore, studies

CJE and CM conceived and designed the study and supervised all aspects of the study. EAA and CJE performed animal experiments. EAA performed ex vivo experiments, image- and statistical-analyses. Results were interpreted by EAA, CJE, and CM. EAA wrote the initial draft of the paper with input, revisions, and approval from all authors. Correspondence to be addressed to CJE. All authors read and approved the final manuscript. This is an Open Access article distributed under the terms of the Creative Commons Attribution License.
in cultured cerebral endothelial cells and in vivo adult rats have shown that the BBB is dysfunctional after hypoxia/ischemia and that a TJ-barrier is formed early in development has been shown in a range of mammals including humans.

Given that TJ-proteins have been suggested as potential biomarkers in adult brain injury models, we hypothesised that BBB related proteins could be detected in blood and cerebrospinal fluid (CSF) after neonatal HI. In this study we focused on three of the key TJ-proteins in the brain endothelium, claudin-5 (CLDN5), occludin (OCLN) and zonula occludens protein 1 (ZO-1). CLDN5 is an integral transmembrane TJ-protein expressed by brain vascular endothelial cells adhering neighbouring cells together and sealing up the paracellular space between the cells of the BBB with structural support from the intracellular scaffold protein ZO-1 while OCLN acts as a regulator of TJ-function and remodelling. In order to study the role of TJ-proteins in neonatal brain injury we used a well-established model wherein a HI brain-injury is induced in post-natal day (PND) 7 rats by ligation of the left common carotid artery combined with a period of hypoxia, the brains of PND 7 rats approximates near-term human infants. This model has been developed to approximate cerebral hypoxia-ischemia believed to be part of the aetiology of infants affected by NE. Circulating TJ-proteins in blood plasma and cerebrospinal fluid (CSF), brain injury and BBB function after injury were determined.

Methods
Animals
Postnatal day 7 (PND7) Wistar rat pups were bred inhouse at the Laboratory for Experimental Biomedicine of Gothenburg University (parents were sourced from Janvier Labs, Le Genest-Saint-Isle, France) and maintained under normal housing conditions with a 12 h light/dark cycle and free access to water and standard laboratory fodder. Animals of both sexes and different litters were used for the experiments and care was taken to minimise the number of animals used and to maintain an even sex-balance in all experimental and control groups. All experiments were approved by the Gothenburg Committee of the Swedish Animal Welfare Agency (Application nos. 663/17) and performed in accordance with the ARRIVE guidelines. A total of 104 animals were used throughout the study.

Hypoxia–ischemia (HI)
PND7 rats were anaesthetised with isoflurane (3.5–5%, Vetmedic, Stockholm, Sweden) in a 50/50 oxygen/nitrogen mixture, placed on their backs and a small incision was made in the neck to gain access to the carotid artery. A suture was placed permanently around the left carotid artery and the incision sealed with Vetbond tissue adhesive (3M, MN, USA). Surgery typically lasted for 3–5 min. Following surgery, pups were allowed to recover in their home cage together with their mother for 1 h. Subsequently, operated pups were placed in a 36°C chamber. The chamber was perfused first with humidified air for 10 min followed by 8% oxygen for 1 h and then by humidified air for 10 min. After the hypoxic exposure, pups were returned to their home cages. Control animals was subjected to sham-surgery (anaesthesia and incision) but no hypoxia. During all procedures, animals were monitored for vitals (i.e. breathing and skin-colour); every animal in the study survived the surgery and hypoxia.

Sample collection and processing
For all time-points after HI (i.e. 6 h, 24 h and 5 days) injured and control animals were euthanised with a lethal overdose of pentobarbital. Cerebrospinal fluid was collected from the cisterna magna through glass capillaries as described previously and blood was collected by cardiac puncture with ethylenediaminetetraacetic acid (EDTA)-treated syringes. CSF was checked for blood contamination as previously described and samples discarded when contamination detected (detection limit about 0.2%). Blood samples were centrifuged at 2000xg for five min to separate the plasma. Samples were placed on dry ice after collection and long-term stored in –80°C freezer until analysed. Whole brains (excluding the cerebellum and brain stem) were collected and immersed in cold 6% buffered formaldehyde (Histofix; Histolab, Gothenburg, Sweden) at 4°C for 24 h before processing for paraffin embedding.

Caspase-3 activity assay
The activity of cleaved caspase-3 at 6 h (n= 7) and 24 h (n= 7) after HI was measured using a fluorometric assay based on an earlier study. Whole brain hemispheres where homogenised in cold RNaše free phosphate-buffered saline (PBS) and sonicated in cold RNaše free PBS containing 2% protease inhibitor cocktail (Sigma-Aldrich, MO, USA) and 10 mM EDTA. Aliquots were centrifuged at 10 000xg for 15 min in 4°C and some supernatant were used for bichinonic acid concentration measurements. For caspase-3 activity, 20 µl supernatant were incubated with 80 µl extraction buffer composed of a buffer base (50 mM Tris, 100 mM NaCl, 5 mM EDTA, 1 mM egtacidic acid, pH 7.3) and 0.2% 3-(3-cholamidopropyl)dimethammonio-1-propanesulfonate, 1% protease inhibitor cocktail, and 1 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich) on a 96 well plate for 15 min in room temperature (RT). 100 µl assay buffer made up of buffer base plus 4 mM diithiothreitol, 1 mM PMSF and 25 µM caspase-3 substrate (Peptides International, KY, USA) were added to the wells before the plate was read for 2 h at 37°C with 2 min intervals on a SpectraMax Gemini EM microplate reader (Molecular Devices, CA, USA) set to excitation wavelength 380 nm and emission wavelength 460 nm. Endpoint readings were made before and after 10 µl of 10 µM free 7-amino-4-methylcoumarin (AMC) (Peptides International) and the Vmax was calculated from the linear part of the curve, caspase-3 activity was expressed as pmol AMC/min-mg caspase-3.

Enzyme-linked immunosorbent assay (ELISA)
Plasma and CSF-samples were analysed using precoated ELISA kits for tight-junction proteins CLDN5 (Nordic BioSite, Stockholm, Sweden), OCLN (Cusabio, Wuhan, China), and ZO-1 (Cusabio) as per the manufacturer’s instructions. Plasma was diluted 20 times and CSF 10 times. In short, standards, CSF and plasma-samples were diluted in sample diluent buffer and incubated on ELISA-plates pre-coated with the antibody. After incubations with a biotinylated secondary antibody, horseradish peroxidase (HRP)-avidin, 3,3′,5,5′-Tetramethylbenzidine substrate, and a stop-solution the optical density was determined with a Spectramax Plus microplate reader (San Jose, CA, USA) set to 450 nm with 540 nm wavelength-correction (OCLN and ZO-1) or 450 nm (CLDN5). The protein concentration was determined from the resulting standard-curve. CSF and plasma from the same animals were analysed for both CLDN5 and OCLN, n= 7–8 for all time-points. Due to some differences between ELISA-plates, all data were normalised to the median of time-matched controls analysed on the same plate.

Blood-brain barrier assessment
The blood–brain barrier permeability was measured using...
radiolabelled sucrose as described by our group earlier. For all time points after HI; 6 h (n = 9), 24 h (n = 8), 5 days (n = 9), injured and PND7 and PND12 control animals (n = 6 for each age) were injected intraperitoneally (i.p.) with two µCi C sucrose (American Radiolabelled Chemicals, MO, USA) in saline (100 µl injection volume). Thirty min later, they were euthanized with a lethal overdose of pentobarbital. Blood was collected through cardiac puncture using a heparinised syringe and centrifuged at 2000g for five min to separate plasma. Choroid plexuses were removed and whole cerebellum and brain stem as well as left and right hippocampus, cortex and striatum/thalamus were dissected and collected into pre-weighed scintillation vials and then re-weighed. 500 µl of Solvable (PerkinElmer, MA, USA) was added to all samples and they were incubated overnight in a 40°C oven to dissolve the tissue. After checking that all tissues were solubilised, samples were left to cool down to RT, mixed with 10 mL Ultima Gold scintillation cocktail (PerkinElmer) and left for 60 min in darkness. The radioactivity in each sample was determined by liquid scintillation counting in a Tri-Carb 4910TR (PerkinElmer) and calculated as cpm/mg sample after correcting for residual blood space in brain. These concentration ratios were used as a measurement of BBB-permeability as previously described after correcting for residual blood space in brain.

BBB-disruption after HI was also tested using injections of Evans blue (EB) dye, a dye that binds to albumin in the blood and thus should be regarded as a high-molecular marker opposed to sucrose. 4% EB dissolved in PBS were injected i.p. (4 µl per g body weight) 6 h post-HI (n = 3) and in control animals (n = 3). After 1 h, animals were euthanized with a lethal overdose of pentobarbital and transcardially perfused with saline and 6% buffered formaldehyde. Whole brains (excluding the cerebellum and brain stem) were collected and immersed in cold 6% buffered formaldehyde at 4°C for 24 h before they were embedded in 4% agarose and cut in 100 µm thick sections in a Leica 1200 VT vibratome (Leica Biosystems, Wetzlar, Germany).

Sections were mounted in water-based CC/Mount (Sigma) and imaged at 680 nm, the wavelength in which emitted fluorescence from EB peaks. EB-extravasation into the brain were quantified in cortical micrographs from injured animals (n = 3) and controls (n = 3). Images were segmented via thresholding, creating binary images of EB area which were measured and calculated as a percentage of the entire image area.

**Measurement of brain blood-vessel area**

Entire hemispheres of CLDN5-stained fluorescent paraffin sections of brains collected five days after HI and controls (n = 5 per group) were imaged with a tiling and stitching function. Two levels (700 µm apart) at midhippocampal level were imaged per animal and analysed with an in-house developed macro for the Fiji-build of ImageJ that utilises difference of Gaussian to eliminate all background while preserving all vessel information to accurately measure the area of blood vessels in an image. Briefly, entire CLDN5-stained brain hemispheres were imaged in a fluorescent microscope (Additional file 1: Figure S1a); the process is shown in a smaller selection of the image (Additional file 1: Figure S1b) for clarity. A copy of the image was subjected to Gaussian blur with sigma=10 (Additional file 1: Figure S1c). The blurred image was subtracted from the original and threshold applied with Fiji’s “analyse particle”-tool to filter out any eventual debris so only marked blood vessels remained (Additional file 1: Figure S1d). The resulting vessel-image were then superimposed on the original image (Additional file 1) to confirm accurate vessel labelling. Blood vessel area was quantified in both injured and uninjured hemispheres by first outlining a region of interest (ROI) delineating the entire cortex and hippocampus and measure the total tissue area. Then the area of marked blood vessels within the ROI was determined and the percentage of blood vessel area of the total area in the hemisphere was calculated. Averages were calculated from the two mid-hippocampal levels per animal. Investigators were blinded to treatment groups during analysis.

**Immunohistochemistry and microscopy**

Paraffin-embedded brains were cut in seven µm thick coronal sections at six levels and 40 sections apart with a microtome, starting at what corresponds to approximately -2.5 mm from bregma in an adult rat. For 3',3'-diaminobenzidine (DAB) immunohistochemistry (IHC), sections were deparaffinised by 30 min incubation at 65°C followed by xylene, and decreasing gradients of ethanol (100% to 70%), and rinsed in dH2O. Antigens were retrieved by boiling in citric buffer (10 mM, pH 6) before endogenous peroxidases were blocked with 3% H2O2. Unspecific binding was blocked by incubating sections in serum-free protein block (Agilent Dako, CA, USA) for 1 h in room-temperature (RT) followed by 4°C overnight incubation with primary antibodies (the used antibodies were directed against platelet endothelial cell adhesion molecule (CD31) microtubule-associated protein-2 (MAP-2), CLDN5, and OCLN, diluted in PBS/0.05% Tween20 (see Table 1). After incubation with the appropriate biotinylated secondary antibodies (Vector Laboratories CA, USA) for 1 h at RT, the staining was enhanced by treatment with Vectastain Elite ABC HRP kit (Vector Laboratories). Finally, sections were dehydrated in gradients of ethanol (70–100%) followed by xylene and mounting in Pertex xylene-based mounting media (Histolab). For fluorescent IHC; deparaffinisation, antigen retrieval, blocking, and antibody-incubations were performed as described above before mounting with ProLong Gold Antifade with or without 4',6-diamidino-2-phenylindole/DAPI (Thermo Fisher, MA, USA). Between all staining steps, sections were washed three times with PBS/0.05% Tween20 (except for after blocking). DAB-stained sections were imaged and photographed with a BX60 microscope equipped with a TH4-200 light-source using the cellSens software (Olympus, Tokyo, Japan) and fluorescently stained sections were examined with a Zeiss Axio Imager. Z2 equipped with Colibri 7 LED-light-source and a MRC AcioCam using the ZEN Blue software (Zeiss, Oberkochen, Germany).

**Table 1 The antibodies used for immunohistochemistry**

<table>
<thead>
<tr>
<th>Primary antibodies</th>
<th>Secondary antibodies</th>
<th>Manufacturer (primary antibody)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse-anti-MAP2 (1/1000)</td>
<td>Biotinylated horse-anti-mouse (1/250)</td>
<td>Sigma-Aldrich, M4403</td>
</tr>
<tr>
<td>Rat-anti-mouse CD31 (1/100)</td>
<td>Donkey-anti AF 594 (1/250)</td>
<td>BD Pharmingen, MEC 13.3</td>
</tr>
</tbody>
</table>
Quantification of CLDN5 expression in entire brain hemispheres

CLDN5 immunoreactivity was quantified in brightfield micrographs of entire brain sections from all time points after HI. For each image, separate ROIs were drawn around the left and right hemisphere and the images were, similarly to the EB-studies above, segmented via thresholding into binary images with CLDN5-positive areas marked. CLDN5 immunoreactivity was calculated as a percentage of the entire hemisphere area.

Brain injury and tight-junction protein level

To test correlation of tight-junction protein levels and degree of brain injury, brains, CSF and blood plasma were collected from HI-animals (n = 12) post-HI. The plasma and CSF were analysed for CLDN5 and OCLN with ELISA as described above while the brains were embedded in paraffin and sectioned to assess the brain injury. Grey matter tissue loss in the injured hemisphere was determined in brightfield-micrographs of coronal brain-sections stained for the neuron- and dendrite-marker Microtuble-associated protein 2 (MAP2). The images were analysed in ImageJ by delineating regions of interests encompassing the entire injured or uninjured hemispheres and measuring the MAP2 positive immunoreactivity in each hemisphere by investigators blinded to which groups and animals the images belonged to. The percentage of tissue loss in each level was calculated from the MAP2-positive area with this formula: (MAP2_{uninjured} − MAP2_{injured})/MAP2_{uninjured} × 100. In all animals, the analysis was performed at six levels encompassing the entire brain and the mean tissue loss of all levels was used in the correlation analysis.

Statistics and graphs

Statistical analyses were made using GraphPad Prism version 8.0 for Windows (GraphPad Software, CA, USA). We used one-way ANOVA with Dunnett’s multiple comparison test, and Pearson’s correlations. The Benjamin-Hochberg method (FDR 0.1) was used to control for multiple correction problems when multiple t-tests were conducted. Specific tests are stated in each Figure legend. Principal component analysis was made using Qucore Omics explorer software (Lund, Sweden) where the built-in statistics module was used to test differences between sexes on variables (unpaired t-test). Images were processed in the Fiji build7 of Imagej,6 figures were designed in Affinity Photo and Designer (Serif Europe, West Bridgford, United Kingdom). The variance of the data in the text of the results-section is presented as mean ± SD.

Results

HI induced caspase-3 activation in the injured brain hemisphere

In this model of neonatal HI, the combination of left carotid artery ligation and global hypoxia produces brain injury and tissue loss in the left hemisphere. To confirm injury in all animals the activity of caspase-3, a hallmark of apoptosis, was measured in homogenates from both injured (left) and uninjured (right) hemisphere of HI and control animals (Additional file 2). Virtually no caspase-3 activity was detected in either the uninjured hemispheres of HI-animals 6 h after HI compared to the uninjured hemisphere (p = 0.0344) or control animals (p = 0.028). Caspase-3 activity was further increased in the left hemisphere at 24 h after HI compared to 6 h after HI (p =
HI-injury resulted in time-dependent increased levels of circulating tight-junction proteins CLDN5 and OCLN in cerebrospinal fluid and plasma and ZO-1 in CSF

Levels of CLDN5, OCLN and ZO-1 were measured in CSF and plasma with ELISA at 6, 24 h and 5 days after HI and all time-points were compared with a control group collected and analysed at the same time and on the same ELISA-plate. CLDN5 and OCLN proteins were detected in all samples with levels ranging between ~41 to 1300 pg/ml (plasma), ~100 to 2400 pg/ml (CSF) for OCLN and ~2 to 30 ng/ml (plasma), ~30 to 53 ng/ml (CSF) for CLDN5. Elevated CLDN5-levels were detected in CSF (Fig. 1d) at 24 h post-HI (p = 0.0082), while plasma-concentrations (Fig. 1c) were higher than controls at 6 h (p = 0.0427). There were no difference at later times between HI and controls. Similarly, OCLN concentration in CSF (Fig. 1b) was raised at 6 h (p = 0.0026) after HI while the levels were higher in plasma (Fig. 1a) of HI-animals at 24 h (p = 0.0285). Measured values (mean ± SD) for CLDN5 and OCLN in blood plasma and CSF are available in Additional file 3, ZO-1 was only detectable in 47% of CSF samples. We found great variability in levels between plasma with as high as 2000 pg/mL in one animal but no differences were measured across groups at any time point after HI (Additional file 4).

Principal component analysis (PCA) was performed (dimension reducing) as means of discriminate analysis with the input of all above measured variables for OCLN and CLDN5. HI and control animals were grouped into three distinct groups at 6 h and 24 h after HI (Fig. 2a) whereas at 5 days post-HI (Fig. 2b), no clustering of control vs HI animals was apparent. To test effect of sex on levels of TJ-proteins we performed unpaired t-test between control and HI-animals (n = 5, 2 m, 4 f) and (p = 0.0363) female rats (n = 11), control animals (males n = 7, females n = 9) had no sex-differences in plasma OCLN (p = 0.91) or CSF CLDN5 (p = 0.19) (Fig. 2c). In HI-animals, the average amount of OCLN in plasma were 700 pg/ml for males and 400 pg/ml for females, for CLDN5 in CSF the numbers were 36 ng/ml for males and 26 ng/ml for females.

**Dynamic changes in BBB function following HI in neonates**

To determine changes in BBB function over time after HI we performed measurements of BBB-permeability in different brain regions (i.e. hippocampus, cortex, and striatum/thalamus) by quantifying the permeability for 14C-labelled sucrose across the BBB. We previously showed that the BBB in the uninjured hemisphere is not altered. We confirmed this (Additional file 5) for the 6 h (controls n = 5, HI n = 5) and 5-day time-points (controls n = 5, HI n = 5) corroborating with caspase-3 activation (Additional file 2). Increased BBB permeability occurred in the ipsilateral hemisphere at 6 h post-HI in the cortex (1.10 ± 0.05, p = 0.0007), hippocampus (1.07 ± 0.08, p = 0.0277),
and striatum/thalamus (1.05 ± 0.05, p= 0.0111) and was also significantly higher at 24 h in both hippocampus (1.12 ± 0.12, p= 0.0486) and cortex (1.18 ± 0.28, p= 0.0474) while the striatum/thalamus appeared unaltered (1.01 ± 0.07, p= 0.7624) (Fig. 3a). Mentionable is that these concentration ratios are probably somewhat affected by the edema occurring in the injured hemisphere after the insult suggesting that the magnitude of BBB permeability increase is likely marginally higher than what these ratios reflect. The concentration ratios 5d post-HI was significantly lower in the injured cortex (0.88 ± 0.12, p= 0.0191) as well as in the entire injured hemispheres (0.91 ± 0.10, p= 0.0303) (Fig. 3b).

BBB disruption following HI were confirmed via assessment of EB-bound albumin extravasation into the brain parenchyma in brain sections. Animals injected with EB at 6 h post-HI showed fluorescence in the cortex of the injured hemispheres (Fig. 3d) while the uninjured hemispheres showed weak fluorescence restricted to blood vessels (Fig. 3e). Control animals injected with EB and not perfused showed distinct blood vessels-restricted fluorescence (Fig. 3f) while animals not injected with EB showed no signal. Extravasated EB encompassed 51.1 ± 8.4% of the total area in images from the injured hemisphere, significantly compared to images from the uninjured hemisphere (6.3 ± 1.9%, p= 0.0002) and controls (5.8 ± 1.6%, p= 0.0002) where the EB was restricted to blood vessels.

The vascular density of the brain is not altered five days after HI
Since the cerebrovascular area, the effective surface area for exchange between blood and brain, can affect measurements of BBB-permeability we developed an in-house written macro for blood vessel analysis of CLDN5 (as a vascular marker) immunolabelled sections. We specifically wanted to estimate cerebrovascular area at later times after injury since there is loss of brain tissue and potentially blood vessels. Sections from brains 5 days post-HI were used to calculate the area of blood vessels in the brain. Two levels were analysed per animal and results averaged (Fig. 3c). For this analysis, the hippocampus and cortex results were combined in each hemisphere. In control animals 2.01 ± 0.64% of the brain area was comprised of vessels while in HI animals vessels comprised 1.53 ± 0.37% of the uninjured hemisphere and 2.05 ± 0.61% in the injured hemisphere. No significant differences were detected between

---

**Fig. 4** CLDN5 immunoreactivity is not altered in the cerebral blood vessels of neonatal rats after HI. Representative double-immunoreactivity for CD31 (red, blood vessel marker) and tight-junctional proteins CLDN5 (green) in cortical brain sections collected 6 h after hypoxia/ischemia (a). Scale-bars are 100 μm in all images. No difference in CLDN5-coverage were seen (b) between controls or either hemisphere in HI-animals at 6 h (2 m, 1f), 24 h (2 m, 1f), 5d (2 m, 1f) post-HI (left in b; p > 0.5) nor between the injured and uninjured hemisphere in HI animals (right in b; p > 0.05). HI, n = 3 per time point, controls (n = 2 per time point). One-way ANOVA with Dunnett’s multiple comparison test and paired t-tests. m male, f female. Bar graphs represent mean values.
CLDN5 immunoreactivity is not altered in the cerebral blood vessels of neonatal rats

Given that there are reports of changes in TJ-protein immunoreactivity following hypoxia/ischemia and hypoxia alone,28,49 we performed double immuno-fluorescent labelling of CLDN5 (Fig. 4a) together with blood vessel marker CD31 (platelet endothelial cell adhesion molecule) in paraffin brain-sections collected at all time points after HI (time chosen given BBB changes). In control animals, we found robust immunoreactivity of TJ-proteins in vessels in all brain regions examined including the cortex, hippocampus, and striatum/thalamus, while no labelling was detectable in parenchyma of the brain. Likewise, in animals after HI we found immunolabelling of blood vessels across all brain regions including MAP2-negative regions with no apparent changes compared to control animals.

CLDN5 immunoreactivity was quantified in DAB-developed sections for CLDN5 only. No significant differences in CLDN5-coverage were seen between HI (n = 9) and control animals (n = 6) (p > 0.05), or between the injured and uninjured hemisphere in HI-animals (p > 0.05), at any time-point (n = 3 per time point) when CLDN5-immunoreactivity was quantified in entire stained brain hemispheres (Fig. 4b).

CLDN5 levels in CSF correlates with brain-injury severity 24 h after HI

The correlation between circulating TJ-protein levels and brain injury severity were investigated 24 h after HI by analysing plasma- and CSF-levels of TJ:s and simultaneously quantifying

control animals and either hemisphere of injured animals (p>0.05).

![Figure 5](image.png)

Fig. 5 CLDN5 levels in CSF correlates with brain-injury severity 24 h after HI. The grey matter tissue loss, defined as the average percentage of negative MAP2 immunoreactivity calculated from six levels throughout the whole brain, correlates with the levels of CLDN5 in the CSF of the same animal 24 h post-HI (a) with a Pearson correlation coefficient (r) of 0.702 (p = 0.016). No correlation was observed between the loss of grey matter and levels of CLDN5 in plasma (c) nor OCLN in CSF (b) or plasma (d). The tissue loss varied between 24.7 to 59.9%, three representative images of injured brain hemispheres are shown in (e), n = 12 (5 m, 7 f). Scale-bars are two mm in all images. m male, f female.
the loss of grey matter in the brain of the same animal. This time-
point was chosen based on the earlier ELISA-results (Fig. 1). The
average brain tissue loss in the HI-group (n = 12) varied from
24.7 to 59.9% (one representative level is shown in Fig. 5b and d,
respectively). By using the Pearson correlation on the levels of
circulating
TJ-proteins and the tissue loss percentages (Fig. 5a), the levels of
CLDN5 in CSF was found to significantly (p = 0.016) correlate
with the severity of the grey matter tissue loss (r = 0.702). No
correlation was observed between the loss of grey matter and
levels of CLDN5 in plasma (r = −0.001) nor OCLN in CSF (r =
0.060) or plasma (r = 0.039).

**Discussion and conclusions**

The brain vasculature is a central component in HI associated
brain injuries that appears damaged early in the injury process
with studies indicating loss of BBB function in response to
neonatal HI. However, diagnostic tools to evaluate brain
vascular dysfunction in neonates in an early, affordable,
available, and reliable manner are lacking. We show elevated
levels of OCLN and CLDN5 in both CSF and plasma in response
to loss of blood-brain barrier function and that CLDN5 levels in
CSF correlates with brain-injury severity. Our data indicate that
loss of BBB function is likely, at least partially, due to molecular
impairment of endothelial tight-junctions after HI injury. The
data suggest that the intermembrane TJ-proteins CLDN5 and
OCLN are putative blood or CSF biomarkers for cerebral
vascular dysfunction and brain damage in neonates.

The cerebrovasculature is specialised in that it harbours a range
of barrier and transport mechanism not found in peripheral
blood vessels, which compartmentalises the brain from the
rest of the body so that brain cells can function in a controlled
environment and provides protection for the brain from potential
harmful blood solutes. These mechanisms are normally referred
to as the blood–brain barrier and an essential part are the tight-
junctions localised to the luminal side of the inter-endothelial
contact forming a physical barrier between blood plasma and
brain. The protein architecture of these junctions is complex
with both inter- and intracellular elements. In this study we
focused on two intracellular TJ-proteins, CLDN5, which are
specific and essential for normal BBB function and, OCLN,
which plays a role in BBB modulation. We made measurements
of both BBB function together with measurements of TJ-
proteins in both CSF and plasma in order to interpret data in an
integrated manner.

We found time-dependent changes in both BBB function and
TJ-proteins levels following HI. Detection of Evans blue in the
injured region of HI-injured animals confirmed BBB-disruption
following HI and the BBB permeability was acutely increased
following HI in rat neonates in agreement with earlier rat
studies and with a similar time line to what we have seen in
mice. Clinical data show about five times higher albumin
CSF/blood ratios of babies diagnosed with NE indicative of BBB
damage also in human newborns, although such ratios should be
interpreted with caution. Overall, the greatest changes in BBB-
opening appeared to be in the cortex, the region most affected
in this HI-model of rats. However, we also see a correlation
between severity of injury and BBB opening in the different brain
regions, similar to the earlier mouse study.

OCLN in CSF was significantly increased 6 h after HI while levels
in plasma increased at 24 h. Levels of CLDN5 on the other hand
were elevated in plasma at 6 h post-HI, while levels in CSF were
higher than normal at 24 h. Levels of CLDN5 and OCLN appeared
to be normalised in both plasma and CSF five days after HI.
CLDN5 was more concentrated than OCLN in both plasma and
CSF. High levels of ZO-1 could only be measured in the CSF in
some of the animals and was not detectable in plasma, thus it
appears that ZO-1, being an intracellular protein, is not as readily
released into the blood after BBB damage. Ischemia has been
shown to induce matrix metalloproteinase (MMP)-mediated
disruption of TJ-proteins, thus altering the cellular distribution
of CLDN5 and OCLN in neonatal mice and adult rats and
seemingly releasing some TJ-proteins into the circulation.

Pan et al. measured the levels of tight-junction proteins in
blood up to 4.5 h after the induction of ischemic stroke via
middle-cerebral artery occlusion (MCAO) in adult rats and saw
a significant increase of circulating OCLN and a molecular loss
of OCLN from cerebral microvessels at 4.5 h post-MCAO while
reporting no differences in blood-CLDN5 levels. A follow up
study yielded similar results in adult rats after MCAO as well
as showing that blood OCLN was elevated in human stroke
patients within 24 h and up to 3d after stroke onset, the levels
of OCLN in blood was reduced after treatment with normobaric
hyperoxia which inhibits MMP-9 activity. While we cannot
directly compare our results to their studies as they have utilised
adult animals in another model, it is evident that focal stroke and
MCAO leads to an increase in blood OCLN levels earlier than in
our neonatal model where we see a peak in blood OCLN 24 h
after HI.

The raised levels of TJ-proteins in both CSF and plasma indicate
that BBB dysfunction after neonatal HI injury is likely to be at
least partially due to direct molecular damage to the endothelial
TJs. Intriguingly, the raised levels of circulating OCLN and
CLDN5 did not occur at the same time after HI showing that
these proteins although normally intimately localised do not
appear to be released into these biofluids in the same manner.
The exact cause of this unclear, but it has been shown that OCLN
and CLDN5 are affected differently in the early ischemic stroke
stages with the former being degraded by MMPs and the latter
instead redistributed via the membrane protein caveolin-1. The
complex linking of CLDN5 and OCLN to domains of intercellular
adapter proteins is different, as reviewed by Piontek et al., and
may also play a role in their release from tight-junctions.

Furthermore, we tested whether levels TJ-proteins could reflect
severity of injury, choosing the 24 h time-point since our results
indicated particularly raised levels of CLDN5 in CSF at this time.
This showed that levels of CLDN5 in CSF correlated with the
severity of brain injury while OCLN levels in plasma and CLDN5
showed no correlation. Human studies on circulating TJ-proteins
have only been made in adults, which makes direct comparisons
with our results more difficult, but there are some common
observations. Kazmierski et al. measured TJ-proteins in serum
after ischemic stroke and found that levels of circulating CLDN5
and OCLN could predict clinical deterioration as a result of
haemorrhagic transformation up to 4.5 h after stroke onset, with
the most sensitive measurement being the CLDN5/ZO-1 ratio.
Comparing TJ-levels in blood and CSF as well as BBB-disruption
between controls and a cohort of patients with intracranial
haemorrhage (ICH), Jiao et al. showed that CSF, but not serum,
levels of TJ-proteins are sensitive predictors for BBB-damage
after ICH. These studies and our results implies that the levels
of circulating TJ-proteins indeed corresponds to the severity of vascular and tissue injury, and BBB-disruption following ischemic events in the brain. Their results also agree with our finding that circulating CLDN5 was more abundant than OCLN.

Taken together our study shows that even a moderate opening of BBB in this model results in raised levels of TJ-proteins at early time points after HI which suggests that TJ-proteins are released into the circulation in the early stages of BBB-damage and could act as biomarkers for vascular integrity and possibly also be useful as brain injury predictor. Our results also indicate a sex difference where males have higher levels of circulating OCLN in plasma and CLDN5 in CSF. This resonates well with previous studies that have shown that there is a tendency for male rats to have graver injuries than females after neonatal HI in an almost identical model to the one employed in this study and it is also known that male human infants have a higher risk for NE. Since our study was not specifically designed to investigate sex differences and analysis involved pooling samples from different time-points, further studies would be needed for confirmation of results. CLDN5 and OCLN showed different patterns of release into biofluids indicating that measuring both of them in tandem would give a better interpretation of injury to the brain vasculature after HI. We therefore performed discriminate analysis showing that HI-animals grouped together and were separate from controls up to 24 h after HI when the levels of CLDN5 and OCLN in both plasma and CSF were analysed together.

While TJ-proteins seem to have potential as standalone biomarkers for neonatal cerebral vasculature dysfunction, many studies, as reviewed in Douglas-ascobar and Weiss, and Lx, have focused on biomarkers related to inflammation and brain injury. As the reviews state, the best course of action will most likely be to develop a panel of different markers in conjunction with diagnosis and other monitoring methods of neonatal brain injuries. Promising biomarker-candidates for assessing NE brain injuries include neuronal injury markers such as Tau and neurofilament light proteins, brain injury marker protein S100B, and inflammation-related cytokines like IL-6 and IL-8. The levels of circulating TJ-proteins in blood from human stroke patients has been shown to positively correlate with the levels of S100B and we saw a correlation between white matter tissue loss and the levels of CLDN5 in CSF. We therefore believe circulating TJ-proteins have promise as a marker for vascular dysfunction, which, in combination with markers for inflammation and injury, would increase the discriminatory, and predictive power of a marker panel for NE brain injuries.

Intriguingly, our results indicated that BBB function does not normalise at later times after HI but instead there is an apparent decrease in permeability below normal levels five days after the insult. One explanation could be that there is loss of blood vessels in the brain tissue after HI, which would reduce the surface area for exchange and thus reduce flux between blood and brain. We therefore estimated the cerebrovascular area at 5 days after HI, which showed that the tissue remaining in the injured hemisphere did not differ in vascular area compared to control animals. Thus, loss of blood vessels unlikely explains the difference in measured BBB permeability. We previously demonstrated an upregulation of both CLDN5 and OCLN genes following neonatal HI injury in mice, which could be a response to normalise barrier function and might underlie the decrease in barrier permeability we observed in the present study. Brain blood flow, measured between 3 to 48 h, in the PND 7 rat HI-model have also shown that that cortical blood flow in this model is reduced not until 48 h after injury, indicating that HI could lead to alterations in the vascular physiology. Speculatively, the time-dependent changes in BBB permeability, increased entry rate in the acute phase (6-24 h) followed by decreased entry rate later 5 days could influence the efficacy of drug treatment in relation to their time of administration time. A limitation of the study is the large inter-animal variability in injury, inherent to this model-system of neonatal HI. Furthermore, brain injury is limited to the hypoxic/ischemic hemisphere, unlike human infants which often develop more generalised brain injuries.

Impact statement
- BBB dysfunction following neonatal hypoxia/ischemia is likely in part due to the loss of tight-junction proteins from cerebral blood vessels. BBB breakdown release tight junction proteins and BBB function may be assessed by measuring these proteins in the circulation.
- This is the first study which investigates tight-junction proteins in the CSF and correlate to levels in circulation in a neonatal animal model of brain injury.
- Elevated levels of blood–brain barrier-derived tight-junction proteins Claudin-5 and Occludin can be detected in the circulation at several time-points in a rat-model for neonatal HI, signifying the proteins potential as biomarkers for the brain vascular dysfunction in neonates.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12987-021-00240-9.

Additional file 1: Images showing the process of delineating blood vessels from CLDN5 immunoreactivity in brain sections. Blood vessels in entire hemispheres (a) were delineated, the process is shown in a selection (b) for clarity. By utilizing difference of Gaussian (c) and Fiji's “analyse particle”-tool, blood vessels in entire brain hemispheres were delineated (d). Accurate marking of vessels was confirmed by overlaying the processed image with the original non-processed image (e).

Additional file 2: Hypoxia/ischemia induces caspase-3 activation in the injured brain hemisphere only. Activated caspase-3 could be measured in the injured hemisphere 6h (3m, 4f), and 24h (3m, 4f) post-HI but not in the uninjured hemisphere nor in any hemisphere of control animals. Columns depict mean value, n 7 per group. Unpaired t-tests between groups, significant differences are marked * (p 0.05) or ** (p 0.01). m male, f female. Bar graphs represent mean values.

Additional file 3: CLDN5 and OCLN levels in blood plasma and CSF, mean ± SD.

Additional file 4: Tight-junction protein ZO-1 can be detected in CSF from some, but not all, animals after neonatal hypoxia/ischemia. The levels of ZO-1 in CSF at 6h, and 24h as well as 5d after HI was measured with ELISA. Out of 7-8 animals per group, we could detect ZO-1 in 3-5 CSF samples. Columns depict mean value, one-way ANOVA with Dunnett's multiple comparison test, HI-groups compared to the controls, p < 0.05 for all comparisons. Bar graphs represent mean values.

Additional file 5: BBB-permeability is not altered in right
hemisphere of control animals. Blood/brain 14C-sucrose concentration ratios in the right hemispheres at 6h (3m, 2f) and 5 days (2m, 3f) following HI together with litter-mate controls. Horizontal lines indicate mean value, n 5 per group (mixed sexes), two-way ANOVA between regions and groups for both time-points, p<0.05 for all comparisons. *m* male, *f* female.

**Abbreviations**

AMC: 7-Amino-4-methylcoumarin; BBB: Blood–brain barrier; CD31: Platelet endothelial cell adhesion molecule (CD31); CLDN5: Claudin-5; CSF: Cerebrospinal fluid; DAB: 3, 3’-Diaminobenzidine; EB: Evans blue; ELISA: Enzyme-linked immunosorbent assay; HI: Hypoxia/ischemia; HRP: Horseradish peroxidase; ICH: Intracranial haemorrhage; i.p: Intraperitoneal; IH: Immunohistochemistry; MAP2: Microtubule Associated Protein 2; MAP2: Microtubule-associated protein-2 (MAP-2); NE: Neonatal encephalopathy; OCLN: Occludin; PBS: Phosphate-buffered saline; PCA: Principal component analysis; PMSF: Phenylmethylsulfonyl fluoride; PND#: Post-natal day #; TJ: Tight-junction(s); ZO-1: Zonula occuldens protein 1.

**Acknowledgements**

The authors want to acknowledge the staff at the Centre for Cellular Imaging at the University of Gothenburg for providing assistance in fluorescent imaging and Nazanin Shahbazi for the technical assistance she provided to the Evans blue-experiments.

**Funding**

Open Access funding provided by University of Gothenburg. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Rune och Ulla Amlövs Stiftelse (EAA), Herbert och Karin Jacobsons Stiftelse (EAA), Swedish Research Council (VR-2017–01409 – CM), Åhlén Foundation (CM), Public Health Service at the Sahlgrenska University Hospital (ALFGBG-722491—CM), Swedish Brain Foundation (FO2019-0270—CM), Stockholm County Council (EAA), Swedish Research Council (VR-2017–01409 – CM), Wilhelm and Martinas Landgren Foundations (CJE).

**Availability of data and materials**

The data behind the conclusions of this study are available from the corresponding author upon reasonable request.

**Ethics approval and consent to participate**

All animal experiments were approved by the Gothenburg Committee of the Swedish Animal Welfare Agency (Application nos. 663/17) and performed in accordance with the ARRIVE guidelines.

**Consent for publication**

Not applicable.

**Competing interests**

The Authors declares that there is no conflict of interest with respect to the research, authorship, or publication of this article.

**References**


Are you bubbling?

Babi. Plus is the standard of care for non-invasive ventilation, providing a gentle approach to improve ventilation and optimize neonatal outcomes.

To start optimizing ventilation in your NICU contact us at 4info@respiralogics.com

Babi. Plus®
Pressure Relief Manifold
Babi. Plus Bubble PAP Valve

Baby” Head Band and Circuit Bumpers
Babi. Plus Nasal Prongs

Baby Nose Bumper and RespiraGel Mustache

Babi. Plus®
Bubble PAP Valve

Baby Band for Chin and Head

3545 Airway Drive, Suite 104 • Reno, NV 89511
775 954 0160 • www.respiralogics.com
© 2019 Respiralogics, GaleMed. All rights reserved.
Healthy development of low birth weight (LBW) premature infants’ gut,1 brain,2 and lungs3 are all impaired without the necessary nutrition. With Prolacta’s products as a part of an Exclusive Human Milk Diet, you can safely fortify within the first week of life to provide the necessary nutrition.3

Half of the nation’s level III and IV neonatal intensive care units have seen firsthand just how much our meticulously crafted human milk-based products matter. 63,000 premature infants throughout the world and counting.4

TOGETHER, we are addressing the risks of late, inadequate, and inappropriate nutrition for LBW premature infants.


info@prolacta.com   888.776.5228

©2020 Prolacta Bioscience, Inc. All rights reserved.
MKT-0679 Rev-0 08/20